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Hydrogen sulphide (H2S) is an endogenously produced gasotransmitter with a similar role as 
nitric oxide (NO) which has long been recognised as an important mediator in erectile 
physiology. Several studies have investigated the role of H2S in erectile function and H2S was 
found to exert definitive pro-erectile effects. The aim of this thesis is to elucidate the 
contribution of H2S to erectile response and shed some light on the mechanism(s) involved, 
including any possible cross talk between H2S and NO.  
 
It was observed that NaHS, a H2S-donor, significantly improved the magnitude of erectile 
response to cavernous nerve electrical stimulation in rats. This improvement was associated 
not only with an increase in the systemic H2S concentration and H2S biosynthesis in the 
corpus cavernosum (CC) of these rats but also with increased production of NO in both 
plasma and CC. The cross talk between H2S and NO was evident in this tissue. Further in 
vitro studies revealed that H2S increased endothelial nitric oxide synthase (eNOS) mRNA 
expression and cyclic guanosine monophosphate (cGMP) level. Moreover, H2S also exerted 
an effect on the NO pathway downstream of NOS, namely increasing the expression of both 
the active and inactive forms of soluble guanylyl cyclase (sGC) β1 and stimulating the 
translocation of sGCα1 from the cytosol to the membrane. Overall, H2S seems to play a 
‘supportive’ role with respect to NO pathway in erectile physiology, amplifying NO 
signalling through dual action of increasing NO production and sensitizing the sGC towards 
NO. In addition, studies using castrated animals demonstrated that testosterone is not a 
requirement for the pro-erectile effect of H2S; however, testosterone is clearly implicated in 
this cross talk. High testosterone level seems to favour the cross talk, with H2S boosting NO 
production in this condition while low testosterone seems to cause H2S to ‘switch’ to an NO-
independent mechanism for its pro-erectile effect. Interestingly, H2S seems to act as a backup 
when the NO pathway is compromised. Under condition of high NO (observed in animals 
treated with sildenafil), normal H2S level and production were observed, while under 
vii 
 
condition of low NO (observed in animals treated with NO synthase inhibitor L-NAME), high 
H2S level was observed. Thus, shortage of NO can trigger the production of H2S, which can in 
turn stimulate the production of NO. The finding from this study that exogenous H2S seems to 
stimulate endogenous H2S production also shed some light on the possible auto-regulation of 
H2S through positive feedback. 
 
The pro-erectile effect of H2S was also likely to result from its attenuating effect on the 
RhoA/Rho-Kinase contractile pathway. In this system, H2S was shown to downregulate the 
level of RhoA and Rho Kinase II (ROCK II) proteins which may have direct implication on 
corporal smooth muscle tone.  
 
In summary, findings from this thesis work show that H2S plays an important physiological 
role in erectile function. It is likely to exert its pro-erectile effects through multiple 
mechanisms of action including a complex cross talk with NO as well as modulation of the 
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1.1 Penile structure and innervation 
 
The erectile tissue is comprised of two functional compartments namely the paired corpora 
cavernosa and corpus spongiosum. The corpora cavernosa consist of smooth muscle fibers 
intertwined in the extracellular matrix of collagen and elastin; they are surrounded by multiple 
interconnecting sinusoidal spaces called lacunae and eventually by a thick fibroelastic sheath, 
the tunica albuginea (Figure 1.1) (Lue, 2000). Arterial blood flow to the corpus cavernosum 
(CC) is provided by the cavernosal arteries through branches of multiple resistance helicine 
arteries which lead directly into the lacunae. Venous outflow from the corpus cavernosum is 
provided by subtunical venous plexus which drains blood from the lacunae into emissary 
veins that pierce through the tunica albuginea and eventually into the deep dorsal vein (Banya 
et al., 1989; Porst and Sharlip, 2006). When the smooth muscles of the helicine arteries are 
relaxed, blood inflow to the lacunar spaces increases. Relaxation of the smooth muscle of the 
trabeculae then dilates the lacunae, allowing for the expansion of the erectile tissue against the 
tunica albuginea which in the process, compresses the subtunical venules against the tunica 
(the stretching of the tunica also compresses the emissary veins), restricting the venous 
outflow. Penile erection is achieved through this combined increase in arterial inflow and 
reduction in venous outflow; a process referred to as the veno-occlusive mechanism (Saenz de 
Tejada et al., 1991). Full erection phase is achieved when the increase in intracavernous 
pressure (to around 100 mmHg from 10-15 mmHg in the flaccid state) lifted the penile body 
from its dependent position to an erect state. This is followed by the rigid erection phase 
where the pressure becomes suprasystolic (>120 mmHg) with the contraction of the perineal 
(ischiocavernosus) muscles (Dean and Lue, 2005). 
 
The penis is innervated by both somatic (dorsal) and autonomic nerve fibers (Lue, 2000). In 
the pelvis, they merge to form cavernous nerves. The somatic nerves supply the penis with 
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sensory fibers and are therefore primarily responsible for penile sensation. They also supply 
the perineal skeletal muscles with motor fibers to facilitate the contraction of the pelvic floor 
smooth muscle which would help to increase the corporeal body pressure and subsequently 
help to achieve maximum rigidity and ejaculation (Kandeel et al., 2001). The autonomic 
nerve supplies are comprised of parasympathetic and sympathetic branches, which are 
involved in the initiation and inhibition of erection respectively (Steers, 1994). The 
parasympathetic nerve fibers divide into two different nerve terminals upon entering the CC: 
1) cholinergic (acetylcholine) nerve terminals at endothelial cells and 2) non-adrenergic, non-
cholinergic (NANC) nerves ending at cavernosal smooth muscles (Adaikan et al., 1991). 
Erection inducing/stimulatory neurotransmitters include those from central nervous system 
such as dopamine (via D2 receptors) (Andersson, 2001), melanocortins (via melanocortin 
receptors) (Martin et al., 2002), serotonin (via 5-HT receptor 2C (Stancampiano et al., 1994; 
Millan et al., 1997)), glutamate (Zahran et al., 2000), EP peptides (hexarelin peptide 
analogues), vasoactive intestinal polypeptide (VIP) (Ottesen et al., 1984; Adaikan et al., 
1986); neurotransmitters from the peripheral nervous system such as acetylcholine 
(Andersson, 2001), and NANC such as nitric oxide (NO) (Burnett et al., 1992; Burnett, 2002). 
The sympathetic nervous system mediates corporal vasoconstriction and smooth muscle 
contraction and therefore, has a role in maintaining penis in flaccid state as well as in 
mediating detumescence after orgasm. The sympathetic nerve fibers innervate cavernous 
smooth muscle (stimulating α1 adrenoceptors) and cavernous vessels (stimulating mostly α2 
adrenoceptors in penile and cavernous arteries (Andersson and Wagner, 1995) and mostly β2 
adrenoceptors in helicine arteries (Saenz de Tejada et al., 1996)). 
 
Generally, penile erection is associated with relaxation of the corporal smooth muscle and 
flaccidity with contraction. The relaxation of the smooth muscle in the penile vasculature is 
also as important in erectile physiology as cavernosal smooth muscle relaxation. A balance 
exists between smooth muscle contraction and relaxation and this is regulated for the most 





Figure 1.1 The anatomy and mechanism of penile erection. The cavernous (autonomic) 
nerves regulate penile blood flow during detumescence and erection while the dorsal 
(somatic) nerves are mainly responsible for penile sensation. The mechanisms of erection and 
flaccidity are shown in the inserts (Lue, 2000). 
 
 
1.2 Erectile dysfunction  
 
Erectile dysfunction (ED) is defined as the persistent inability to generate enough corporal 
body pressure necessary for vaginal penetration and/or the failure to maintain this level of 
rigidity in the penis until ejaculation for satisfactory sexual performance (Lizza and Rosen, 
1999). It is a major health concern not only because it can significantly affect the quality of 
life but also because of its relatively high prevalence; the combined prevalence of ED 
(including mild moderate and complete) was estimated to be approximately 52% in men aged 
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between 40 to 70 years (Feldman et al., 1994). It is also strongly associated with age and can 
be correlated with hypertension and heart disease (Feldman et al., 1994). In fact, ED has been 
found to be a likely indicator of systemic vascular disease and may serve as an early warning 
for cardiovascular events such as myocardial infarct or stroke (Speel et al., 2003; Thompson 
et al., 2005; Montorsi et al., 2003b). The risk of ED was found to be 26/1000 every year and 
this incidence increases with age, hypertension, heart disease and diabetes (Johannes et al., 
2000). In the local context, ED is found to be common amongst Singaporean men; the 
prevalence for ED is 42% in forty-year old men and is as high as 77% in sixty-year old men 
(Tan et al., 2003). 
 
1.2.1 Pathophysiology of erectile dysfunction 
 
Erectile physiology is an intricate interplay of vascular, neurologic and endocrine factors, 
making ED a multifactorial disorder that can be difficult to treat. The dysfunction can be 
psychogenic (performance anxiety related) or organic (e.g. as a result of hypertension, 
diabetes, hypercholesterolemia, etc). It can also be caused by pharmacological agents (such as 
anticholinergic, psychotropic, or antihypertensive medications) (Finger et al., 1997; 
Crenshaw, 1996). Medications may get implicated in the development or exacerbation of ED 
in several ways: by inhibiting the central/peripheral nervous system, disturbing the 
hypothalamic-pituitary-gonadal axis, including androgen production and metabolism, altering 
the normal haemodynamics of hypogastric-cavernous arterial beds or by disturbing the 
control of the corporal vasomotor system (Goldstein and Krane, 1983). There has also been 
evidence that smoking is associated with vascular pathology (including atherosclerosis in the 
penile arteries) and may be a major risk factor for ED (Mannino et al., 1994). 
 
Organic cause of ED may be systemic such as endocrinal, vascular, neurological or local in 
nature. Systemic diseases such as diabetes mellitus (Feldman et al., 1994; McCulloch et al., 
1980; Hidalgo-Tamola and Chitaley, 2009), renal failure (Palmer, 1999), cancer (Andersen, 
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1985; Cull, 1992) and chronic liver disease (Kew, 1988; Burra et al., 2010) have been 
associated with ED. One of the most common forms of ED is related to vascular 
insufficiency, which includes arterial and venous insufficiency (Mulcahy, 2006). In arterial 
insufficiency, arterial supply is disrupted, usually from atherosclerosis or hypertension, 
resulting in poor penile perfusion. Venous insufficiency or leakage refers to inadequate 
trapping of blood in the corpora which may be caused by intrinsic abnormality in the smooth 
muscle, incomplete smooth muscle relaxation, or primary veno-occlusive dysfunction 
(Mulcahy, 2006). Chronic central nervous system disorders (e.g. Alzheimer’s or Parkinson’s 
disease, stroke), spinal cord injuries (trauma), or diabetes mellitus (Lue, 2000) may also affect 
the erectile pathway, reflexogenic erections and/or erectile response to psychogenic stimuli 
(Smith and Bodner, 1993; Courtois et al., 1993). Similarly, local penile disorders such as 
Peyronie’s disease (Hellstrom and Bivalacqua, 2000; Lopez and Jarow, 1993; Ralph et al., 
1996), phimosis (Alexander, 1993; Morgentaler, 1999), priapism (El-Bahnasawy et al., 2002), 
or any congenital penile malformations/anomalies (Matter et al., 1998) may interfere with 
normal erectile function resulting in ED. 
 
1.2.2 Management of erectile dysfunction 
 
There are several ways in which ED can be managed. These include psychological and 
behavioural counseling, drug therapy, the use of non-surgical devices (e.g. vacuum pump and 
constrictive ring), or surgery (e.g. repair of penile abnormality, penile prosthesis implantation, 
arterial revascularization or venous ligation) (Kandeel et al., 2001). The choice of treatment 
should be considered based on the etiology behind the dysfunction. Generally, patients 
presenting with ED that is secondary to an underlying disease should be treated for the 
primary pathology, e.g. diabetic men with better glycemic control have been found to have 
lower odds ratio for ED (Fedele et al., 1998). Some drug therapies that have been used with 
varying success, are reproductive hormones (androgen replacement in hypogonadal men 
presenting with ED) (Arver et al., 1996; Mulhall, 2004), α2-adrenoceptor antagonist 
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(yohimbine) (Ernst and Pittler, 1998), centrally-acting drugs such as dopaminergic agonist 
(apomorphine) (Altwein and Keuler, 2001), and long-acting opiate antagonist (naltrexone) 
(Brennemann et al., 1993). Besides systemic medications, local vasoactive agents can also be 
administered through direct intracavernosal injection (for example papaverine, phentolamine 
(Dinsmore, 1990), prostaglandin E1 (PGE1, alprostadil) (Virag and Adaikan, 1987), and VIP 
(Adaikan et al., 1986)), or transurethral application (e.g. alprostadil) (Montorsi et al., 2003a). 
 
There are 11 known families of phosphodiesterase (PDE) enzyme systems, comprising of at 
least 60 distinct species, each differing in its kinetic properties, substrate specificity and tissue 
distribution (Bischoff, 2004). Phosphodiesterase type 5 (PDE-5) is the predominant cGMP 
metabolizing enzyme in penile arteries and CC, but it is also localised in lungs, platelet and 
vascular smooth muscle cells. Sildenafil, a classical PDE-5 inhibitor, approved in March 1998 
and its successors have emerged as the first line of treatment and still are the most widely 
prescribed oral therapy for ED (Montorsi et al., 2003a; Al-Shaiji and Brock, 2009), mainly 
because of their ease of use, efficacy and relatively low incidence of adverse effects (Fazio 
and Brock, 2004). Sildenafil is also known to be highly selective for PDE-5, compared to 
other PDEs (Bischoff, 2004). However despite its general efficacy, there remains a 
subpopulation of patients with ED (about 30-40%) who are resistant to this treatment 
regimen, necessitating a search for alternative approaches (Hatzimouratidis and Hatzichristou, 
2005). Sildenafil works by inhibiting PDE-5, the enzyme that breaks down 3’5’-cyclic 
guanosine monophosphate (cGMP) - an important mediator in erectile physiology involved in 
smooth muscle relaxation - to 5’-GMP (Corbin and Francis, 1999), effectively increasing the 
cGMP level and thereby amplifying the cavernosal smooth muscle relaxation occurring after 
sexual arousal (Montorsi et al., 2003a). This means that the erectogenic effect of sildenafil 
relies very much on prior release of NO following sexual stimulation (the binding of NO to 
soluble guanylyl cyclase (sGC) increases the activity of the enzyme which would 
subsequently convert GTP to cGMP and increase the cGMP level (Ignarro, 2000)) and/or 
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possibly, the available cGMP pool in the body. Failure of sildenafil therapy that is observed in 
some patients may be attributed partly to insufficient production of NO (Rajfer et al., 2002). 
Agents whose mechanism of action is independent of the NO/cGMP production may prove to 




The neurotransmission in erectile physiology involves both sympathetic and parasympathetic 
pathways of the pelvic region. The sympathetic, anti-erectile neurotransmitter in human 
penile tissue is noradrenergic causing contraction of the CC muscle (Adaikan and Karim, 
1981; Giuliano et al., 1993); this transmitter is the main agent helping to keep the penis in 
rugose state. The parasympathetic neurotransmitter of erection to the cavernosum is not 
cholinergic (that is, not releasing acetylcholine, as it is in some other systems in the body) or 
adrenergic (that is not releasing noradrenaline). This type of neurotransmission was 
discovered and coined as NANC by Burnstock (Burnstock et al., 1964; Burnstock 1972) and 
subsequently was termed ‘nitrergic’ by Rand in 1992 (Rand 1992). The existence of NANC in 
rat anococcygeus and bovine retractor penis muscle was first reported by Gillespie (Gillespie 
1972) and by Klinge and Sjostrand (Klinge and Sjostrand, 1974). Similarly, the identification 
of NANC neurotransmission in the human CC was first reported by Adaikan and Karim 
(Adaikan and Karim, 1978; Adaikan, 1979) and this neurotransmitter was confirmed to be 
nitrergic, releasing NO (Adaikan et al., 1991). 
 
Cellular signaling is usually initiated by the binding of factors or neurotransmitters to 
receptors on the plasma membrane. The resulting interaction between ligand and receptor 
generates intracellular second messengers which then relay the extracellular signals to 
different parts inside the cell, resulting in the modulation of cellular activities. The discovery 
of NO as an endothelium-derived relaxing factor (EDRF) in 1987 (Marsh and Marsh, 2000) 
represents the identification of cellular signaling mechanism that is receptor-independent. It 
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was observed that NO acted like a classical neurotransmitter, but with a different signaling 
mechanism. The term ‘gasotransmitter’ was then conceived to designate this molecule to 
distinguish it from classical neurotransmitters (Wang, 2002). Generally, to qualify as 
gasotransmitters, the molecules must possess the following characteristics: 1) they must be 
endogenously produced; 2) they must be freely permeable to membranes so that their effect(s) 
do not need to rely on membrane receptors; 3) their production and metabolism must be 
regulated; 4) at physiological concentration, they must have specific and well-defined 
function(s); and 5) regardless of whether their effects are mediated by intracellular second 
messenger or not, they should have specific molecular and cellular targets (Wang, 2002). 
Currently three gasotransmitters have been identified: nitric oxide, hydrogen sulphide (H2S) 
and carbon monoxide (CO). 
 
1.3.1 Hydrogen sulphide 
 
1.3.1.1 Overview of H2S 
 
Decades of occupational health and environmental studies have described H2S as a toxic 
pollutant that is detrimental to human health. This perspective has undergone a paradigm shift 
in recent years with the emergence of evidence for profound physiological effects of H2S. 
Hydrogen sulphide seems to be able to exert a multitude of biological effects, having been 
implicated in inflammation (Zanardo et al., 2006), antinociception (Distrutti et al., 2006), 
myocardial ischaemia-reperfusion (Elrod et al., 2007), cardiovascular pathology, shock/sepsis 
(Mok et al., 2004; Collin et al., 2005), pulmonary hypertension, and diabetes (Łowicka and 
Bełtowski, 2007). Essentially, H2S is a lipophilic colorless gas with a ‘rotten-egg’ odor. It is 




 through the 




 ↔ S2- + 2H+. The Henderson–Hasselbalch equation 
predicts that at the physiological pH of 7.4 and temperature of 37°C, 18.5% of the sulphide 
will exist as H2S, with the remaining 81.5% as HS
- 
(Dombkowski et al., 2004). It is still 
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) mediate the observed 
biological effects of H2S (Whiteman and Moore, 2009). 
 
1.3.1.2 Biosynthesis of H2S 
 
Most of the evidence for the physiological role of hydrogen sulphide is based on the 
observation that it is endogenously produced in tissues that are pertinent to its proposed roles 
(either as a vasorelaxant or neuromodulator). This means that the methodologies used to 
accurately measure this gas, which is both labile and present at relatively low concentration, 
must be rigorously assessed in order to avoid potential artifacts. Unfortunately, unlike NO 




), H2S has no 




 cannot be used to 
measure hydrogen sulphide production as they can also be formed from direct oxidation of L-
cysteine with cysteine deoxygenase; refer to Figure 1.2). However, a majority of the studies 
(employing different analytical techniques) reported plasma H2S in similar range (25-80 µM 
in rat and humans) with few exceptions (Whiteman and Moore, 2009), thereby suggesting that 
the measurements are likely to be credible.  
 
Significant amount of H2S is produced in most tissues in mammals including the penile tissue 
(Srilatha et al., 2007), with higher production being observed in brain, liver, kidney, and the 
cardiovascular system (Doeller et al., 2005; Zhao et al., 2003). The majority of the 
endogenous H2S is synthesised from L-cysteine by two pyridoxal-5’-phosphate (vitamin B6) 
dependent enzymes, cystathionine β-synthase (CBS, enzyme commission number (EC 
4.2.1.22)) and cystathionine γ-lyase (CSE, EC 4.4.1.1) (Figure 1.2). The expression of these 
enzymes is tissue-specific; CBS is predominantly found in the central nervous system while 
CSE is expressed mainly in the liver, vascular and non vascular smooth muscles (Szabó, 
2007). Human penile tissue homogenates express both CBS and CSE mRNA and protein 
(d'Emmanuele di Villa Bianca et al., 2009). Another enzyme that can contribute to H2S 
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biosynthesis is 3-mercaptopyruvate sulphurtransferase (MPST). Cysteine (aspartate) 
aminotransferase (AAT) first produces 3-mercaptopyruvate and L-glutamate by catalyzing the 
transamination between L-cysteine and α-ketoglutarate. The enzyme, MPST would then 
transfer sulphur from 3-mercaptopyruvate to sulphurous acid to generate pyruvate and 
thiosulphate which is then reduced to H2S by another sulphurtransferase in the presence of 
reduced glutathione (Tanizawa, 2011). In this way, MPST (together with AAT) is found to 
significantly contribute to H2S generation from L-cysteine in the presence of α-ketoglutarate 
in vascular endothelium of the thoracic aorta (Shibuya et al., 2009a) as well as the brain 
(Shibuya et al., 2009b). Hydrogen sulphide can also be synthesised from L-methionine 
through the trans-sulphuration pathway which involves the formation of homocysteine 
intermediate (Fiorucci et al., 2006). Moreover, non-enzymatic reduction of elemental sulphur 
(inorganic source of H2S) using reducing equivalents from glucose oxidation can also 




Figure 1.2 Enzymatic production of H2S. (Compiled from (Wang, 2002; Szabó, 2007; Chen 





Figure 1.3 Non-enzymatic endogenous production of H2S (Wang, 2002) 
 
 
1.3.1.3 Metabolism of H2S 
 
Hydrogen sulphide is eliminated from the body mainly through the kidney either as 
conjugated or free sulphate. In the cell, catabolism of H2S takes place in cytosol and 
mitochondria. It is metabolised in cytosol through a methylation process by thiol S-
methyltransferase (TSMT) to methanethiol and dimethylsulphide (Furne et al., 2001)
 
and in 
mitochondria through an oxidation process to form thiosulphate, probably through either an 
enzymatic process catalyzed by superoxide dismutase (Searcy, 1996) or a non-enzymatic 
process as part of the mitochondrial respiratory electron transport (Łowicka and Bełtowski, 
2007) (Figure 1.4). This thiosulphate would then be converted to sulphite by 
thiosulphate:cyanide sulphurtransferase (EC 2.8.1.1) and finally to sulphate by sulphite 
oxidase (SO). The H2S can also be scavenged by metallo- or disulphide-containing molecules 
(e.g. oxidised glutathione) or by methemoglobin to form sulphhemoglobin (Wang, 2004). 
Hemoglobin is not only able to bind to H2S; it can also bind to NO to form nitrosyl 
hemoglobin and to CO to form carboxyhemoglobin (Wang, 1998). In this way, it was 
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suggested that the bioavailability of one gas may be modulated by another as the binding by 
one would reduce the binding of the other gases to hemoglobin (Wang, 2002). This balanced 
metabolism at the cellular level means that H2S produced endogenously under physiological 
condition is not toxic to the body as it gets rapidly oxidised in the mitochondria without 
accumulation (Wang, 2004). However, H2S has a steep dose-response curve where the 
physiological effect transformed sharply into a toxic effect (Wang, 2002), as evidenced in 
rodent brain (Warenycia et al., 1989) in which, the toxic level was less than double the 
endogenous level and H2S intoxication also raised the endogenous level only by 57% 
(Mitchell et al., 1993). 
 
 
Figure 1.4 H2S metabolism. (1) mitochondrial oxidation, (2) cytosolic methylation, (3) 
binding to methemoglobin. TST = thiosulphate:cyanide sulphurtransferase; SO = sulphite 





1.3.1.4 Roles of H2S in erectile function 
 
Preliminary study from our lab demonstrated that administration of sodium hydrosulphide 
hydrate (NaHS.xH2O, a stable donor of H2S) in vivo increased the penile length, penile 
perfusion and intracavernosal pressure (ICP) in non-human primates (Srilatha et al., 2006). 
This is the first direct evidence for the pro-erectile effect of H2S in CC. Since then, such 
facilitatory effects on erectile function have also been observed in other animal models; NaHS 
is shown to dose-dependently relax pre-contracted rabbit (Srilatha et al., 2007) and human CC 
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(d'Emmanuele di Villa Bianca et al., 2009) in organ bath studies while CSE inhibitor (DL-
propargylglycine, PAG) is shown to lower the ICP in rats in vivo (Srilatha et al., 2006). 
Similar to NaHS, L-cysteine - the H2S precursor and CBS/CSE substrate - can also increase 
ICP and this effect is inhibited by PAG (d'Emmanuele di Villa Bianca et al., 2009).  
 
The classical inhibitor of adenylyl cyclase (AC), cis-N-(2-phenylcyclopentyl)-azacyclotridec-
1-en-2-amine hydrochloride, (MDL 12330A) is able to block H2S-induced relaxation in pre-
contracted rabbit CC but this inhibition appears to be incomplete (Srilatha et al., 2007), 
suggesting thereby that while the cyclic adenosine monophosphate (cAMP) pathway is likely 
to be implicated in the mechanism of action of H2S, it is not the only pathway and that there 
are other likely mechanism(s) that contribute(s) to the relaxant effect of H2S. Furthermore, 
inhibition of endogenous H2S production with PAG or the CBS inhibitor aminooxyacetic acid 
(AOAA) can also significantly increase the contraction induced by electrical field stimulation 
at different frequencies in rabbit (Srilatha et al., 2007) and human (d'Emmanuele di Villa 
Bianca et al., 2009) CC; this type of contraction is usually associated with detumescence. 
Taken together, the evidence suggests that the effects of H2S may be twofold; being involved 
in 1) the relaxation of the corporal smooth muscle; and 2) the inhibition of the penile basal 
tone. The nature and site of H2S effects (molecular/cellular/neurovascular) are unknown at 
this stage, but the finding has been significant considering that both impaired relaxation and 
increased contractility can contribute to ED. 
 
In the human CC, CBS and CSE are found to be localised mostly in the vascular and 
trabecular smooth muscles (d'Emmanuele di Villa Bianca et al., 2009). Moreover, the relaxant 
effect of H2S appears to comprise of both endothelium-dependent and -independent 
components. This dual property of H2S may have significant implication considering that one 
of the major contributing factors to penile vascular pathology in ED is endothelial dysfunction 
(Bivalacqua et al., 2003). The novel H2S pathway, by virtue of its lack of dependence on the 
integrity of the endothelium (which may be compromised in ED patients) for its production, 
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may aid in the relaxation of the cavernosum particularly in pathological conditions where 
endothelial nitric oxide synthase (eNOS) function is impaired (See Liaw et al., 2011). 
 
Studies on the vascular system show that H2S causes vasoconstriction at low concentration 
but vasodilatation at high concentration (Kubo et al 2007a). This vasorelaxant effect involves 
potassium channel conductance, particularly K
+
ATP channel but not KCa or KV (Zhao et al., 




channel currents, cause hyperpolarization (giving rise 
to the closure of voltage-dependent Ca
2+
 channel which decreased the intracellular Ca
2+
 to 









channels are expressed in human CC (Insuk et 
al., 2003); they have a functional role in penile resistance arteries (Ruiz Rubio et al., 2004) 
and are important in the modulation of corporal smooth muscle tone and may well serve as 
targets for neurotransmitters (Christ, 2002). However, this K
+
ATP-dependent mechanism does 
not appear to be exclusive for H2S since glibenclamide (K
+
ATP channel blocker) only partially 
inhibited H2S-induced vasorelaxation (Zhao et al., 2001). It is also proposed that the relaxant 
effect of H2S may be mediated via a mechanism that involves metabolic inhibition, changes in 




 channels (Kiss et al., 2008).  
 
The pro-erectile effect of H2S seems to extend beyond its immediate relaxant activity in the 
penis. At the cellular level, H2S is involved in modulating the level of anti-erectile 
proteins/factors which are pathophysiological in nature. In human vascular smooth muscle 
cells (hVSMCs) (Muzaffar et al., 2008b) and pulmonary arterial endothelial cells (Muzaffar et 
al., 2008a), H2S can inhibit nicotinamide adenine dinucleotide phosphate-oxidase (NADPH 
oxidase) activity and expression. This enzyme is a major source of superoxide (O2
-
) in the CC 
smooth muscle, being involved in the reduction of oxygen to superoxide (Babior, 2004). 
Elevated superoxide level is one of the known causative factors of ED (Jeremy et al., 2006) 
and many factors associated with ED such as cytokines, angiotensin II and thromboxane A2 
can also increase NADPH expression (Muzaffar et al., 2005; Hotston et al., 2007). 
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Superoxide anion can upregulate the expression of PDE-5 and react with NO to form the 
reactive oxygen species peroxynitrite (ONOO), which not only causes a reduction in the level 
of bioavailable NO but also causes tissue injury and alteration in the vascular tone (Figure 
1.5) (Jones et al., 2002). By reducing NADPH expression and activity, H2S can help to 
abrogate the effects of superoxide anion especially under pathological conditions and boost 
the erectile capacity. The concentration at which H2S exerts this inhibitory effect is much 
lower than that which causes relaxation (Shukla et al., 2009), suggesting that the potential of 
H2S lies not only in its acute pro-erectile effect but also in its longer term effect in 




Figure 1.5 H2S as an inhibitor of superoxide formation. (+) = stimulation; (–) = inhibition. 
Red arrows represent possible hypothetical pathways that have not been proven (Hotston et 




1.3.2 Nitric oxide 
 
1.3.2.1 Overview of NO 
 
With the arrival of the industrial revolution, natural gases such as NO were viewed by the 
public as atmospheric pollutant and toxic waste. Nitric oxide is emanated from industrial 
processes and motor car exhausts (Bruckdorfer, 2005); it can also be generated by lightning in 
the troposphere (Levine et al., 1984) or released by nitrifying bacteria in the soil (Conrad, 
1996).  Nitric oxide is essentially an odourless, colourless, lipophilic and soluble diatomic gas 
which is also a free radical (Bruckdorfer, 2005). In 1980, Furchgott and Zawadski discovered 
an agent of endothelial origin, that relaxed the arterial smooth muscle and not knowing the 
identity of the agent at that time, they referred to it as the EDRF (Furchgott and Zawadzki, 
1980). It was only seven years later that the identity of EDRF was revealed to be NO (Ignarro 
et al., 1987b; Ignarro et al., 1987a). Nitric oxide is now recognised as an important ubiquitous 
intercellular signalling molecule in many tissues. It has antiplatelet aggregatory and anti-
inflammatory properties, both pro- and anti-angiogenic activity and can decrease leukocyte 
adhesion (Wang, 2004). 
 
1.3.2.2 Biosynthesis of NO 
 
Nitric oxide is biosynthesised from L-arginine (an amino acid that is present at high 
concentration in the blood, extracellular fluid and inside the cell) through a series of redox 
reaction involving several co-factors with specific binding sites, and producing L-citrulline as 
by-product (Bruckdorfer, 2005). The co-factors include tetrahydrobiopterin (BH4), 
nicotinamide adenine dinucleotide phosphate (NADPH), flavin mononucleotide (FMN), 
flavin adenine dinucleotide (FAD) and calmodulin (Figure 1.6) (Li et al., 2009b). The 
guanidine nitrogen of L-arginine is oxidised, eventually forming the nitrogen of NO while the 
oxygen in NO is derived from molecular oxygen (Li et al., 2009b). This reaction is catalyzed 
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by nitric oxide synthase (NOS), of which there are three isoforms: neuronal NOS (nNOS), 
inducible NOS (iNOS), and eNOS (Wang, 2004). These isoforms are found on different 
chromosomes with different subcellular localization and mode of regulation. The two 
isoforms, nNOS and eNOS, are constitutively expressed in a cell-specific manner, producing 
low amounts of NO (in pico to nanomolar range) (Moncada et al., 1991) and can be activated 
by calcium binding to calmodulin (Li et al., 2009b). They are regulated mainly at the post-
translational stage (Bivalacqua et al., 2002). Under certain pathological condition, eNOS 
activity may be altered, for example eNOS is inhibited in diabetic hyperglycemia through a 
post translational modification involving protein kinase B (PKB, also known as Akt) (Du et 
al., 2001). Shear stress is also thought to activate eNOS, possibly through the activation of 
calcium channels (Lin et al., 2000). Inducible NOS is a calcium-independent isoform of NOS; 
its expression can be induced by inflammatory mediators or immunological stimuli such as 
cytokines or bacterial lipopolysaccharide (LPS), producing higher amounts of NO (in nano to 
micromolar range) (Wang, 2004).  
 
It is known that nNOS generates NO in the nerves of the central and peripheral autonomic 
nervous system. Nitric oxide is released from the NANC nerves that innervate the visceral 
smooth muscle (Adaikan et al., 1991; Rand and Li, 1995). The NO released mediates smooth 
muscle relaxation and is involved in regulating bronchodilation, sphincter function, and 
gastrointestinal motility (Wang, 2004). The nNOS is located mainly in the mitochondria and 
cytoplasm of the cell (Jobgen et al., 2006) while eNOS is expressed by endothelial cells; it is 
located within the caveolae of the plasma membrane but is also present in the cytoplasm 
(Jobgen et al., 2006). On the other hand, iNOS is produced by macrophages, neutrophils and 
vascular smooth muscle cells (Bishop-Bailey et al., 1997) and is mostly localised in the 
cytoplasm (Jobgen et al., 2006). Almost all cell types are able to recycle citrulline back into 
arginine through the argininosuccinate synthase (ASS) and argininosuccinate lyase (ASL) 
pathway (Wu and Brosnan, 1992). This recycling helps to ensure that there is sufficient 
concentration of arginine for production of NO. The main site of NO production in human CC 
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is in the terminal branches of the cavernous nerves that supply the erectile tissue (Burnett et 
al., 1993) where NO is formed through the activity of nNOS in the NANC neurons (Burnett et 
al., 1992; Cartledge et al., 2001) and eNOS in the endothelium (Hurt et al., 2002). 
 
Biosynthesis of NO is dependent on the availability of the substrate L-arginine and the 
various co-factors (in particular BH4 (Ignarro, 2000)) that are needed for the NOS enzyme 
activity. Even though the concentration of L-arginine within and outside the cell is usually 
well above the saturation point of the enzyme, under conditions where endothelial function is 
impaired, L-arginine level may be a limiting factor (Bruckdorfer, 2005). Biosynthesis of NO 
may also be partly influenced by the presence of naturally occurring NOS inhibitors inside the 
cell or in the blood e.g. asymmetric dimethylarginine or L-monomethyl arginine which is a 
naturally occuring competitor of L-arginine (Li et al., 2009b). Nitric oxide can also be 
produced through a non-enzymatic process. Nitrite, on its own has negligible relaxant activity 
but under acidic condition, it can be reduced back to NO. The conjugated acid of nitrite can 
react with another nitrite to generate N2O3, which then releases NO (Zweier et al., 1999). 
 
 
Figure 1.6 Synthesis of NO from L-arginine. AS = argininosuccinate; BH4 = 
tetrahydrobiopterin; ASL = argininosuccinate lyase; ASS = argininosuccinate synthase; Asp = 
L-aspartate (Li et al., 2009b). 
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1.3.2.3 Metabolism of NO 
 
The mode and rate of NO metabolism in the body depends on several factors, including the 
concentration of NO itself, its diffusibility and the surrounding concentration of other 
bioreactants. Having a neutral charge, NO has high diffusion capacity, being able to diffuse in 
aqueous solution, across membranes and over long distances in tissues (Kelm, 1999). When 
exposed to oxygen, NO can produce reactive nitrogen oxide species e.g. nitrogen dioxide 
(NO2) and nitrogen trioxide (NO3). Nitric oxide also undergoes auto-oxidation to release NO2 
in aqueous solution which can undergo further reaction to form nitrite (NO2
-
) and nitrate 
(NO3
-
) (Wang, 2004). 
 
The auto-oxidation kinetics of NO in aqueous solution is dependent on its concentration (Ford 
et al., 1993) and therefore the half-life (T1/2) of NO is not a constant value and is in fact 
inversely related to NO concentration (Kelm, 1999). This means that the T1/2 of NO becomes 
longer as NO gets more dilute. As NO moves away from its site of origin, it will get diffused 
and its concentration will drop with distance. With a lower NO concentration, its lifetime 
increases and this results in a higher effective ‘bioavailability’ of NO, allowing it to react with 
other biological molecules e.g. plasma proteins, oxyhemoglobin, or sGC enzyme (Wink and 
Mitchell, 1998). Nitrite and nitrate are considered stable end products of NO metabolism and 
they are both excreted by the kidneys. Collectively, their level can be used as a measure of 
NO synthesis in the body (Kelm, 1999).  
 
Endogenous biotransformation of NO occurs through different metabolic routes. Essentially, 
it can react rapidly with superoxide anion to form peroxynitrite (Huie and Padmaja, 1993). In 
the blood, NO can also get oxidised by oxyhemoglobin to produce nitrate and methemoglobin 
(Kelm, 1999). The cysteine residue of globin in hemoglobin functions as a reversible carrier 
of NO for delivery to tissues (Allen et al., 2009). Reacting with thiols, NO may form S-
nitrosothiols (RSNO) with a longer T1/2 than NO, which is important for its stability and 
20 
 
transport; RSNO also serves as a stable reservoir of NO (Wang, 2004). Superoxide dismutase 
(SOD) – scavenger of superoxide anion – can also protect NO since NO is inactivated by 
superoxide and in this way, SOD can indirectly enhance the availability and duration of action 
of NO (Kelm, 1999; Wang, 2004).  
 
1.3.2.4 Roles of NO in erectile function 
 
As mentioned earlier, NO is an important neurotransmitter of human penile erection (Adaikan 
et al., 1991). Nitric oxide released from nerve endings and endothelial cells activates sGC 
which mediates increased conversion of guanosine triphosphate (GTP) to cGMP (Ghalayini, 
2004). Cyclic GMP governs many aspects of cellular function through its interaction with 
cGMP-dependent protein kinases, cyclic nucleotide phosphodiesterases or cyclic nucleotide 
gated-ion channels (See Ignarro, 2000). It can also stimulate protein kinase G (PKG), which 
would in turn initiate the phosphorylation of membrane-bound proteins at K
+
 channels (See 
Francis et al., 2010). This leads to K
+ 
ions outflow into the extracellular space, 
hyperpolarizing the cells (Figure 1.7) to bring about closure of L-type Ca
2+
 channels with a 
resultant drop in intracellular Ca
2+ 




 and calmodulin activate the myosin light chain kinase 
(MLCK), whose function is to catalyse the phosphorylation of myosin light chain (MLC) and 
induce actin-myosin interaction, which is necessary for cavernous smooth muscle contraction 
in the non-erect state (Gao et al., 2001). The decrease in intracellular Ca
2+
 brought about by 
NO leads to reduced activation of MLCK, resulting in decreased phosphorylation of the MLC 
and reduced actin-myosin interaction, eventually leading to corpus cavernosal relaxation and 
erection. Vasoconstrictors like endothelin-1 (ET-1) and norepinephrine stimulate the activity 
of phospholipase C to increase inositol triphosphate (IP3) and diacylglycerol (DAG), resulting 
in increased intracellular Ca
2+
 phosphorylation of MLC and smooth muscle contraction - NO 
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reverses this process by increasing cGMP level (Figure 1.7) (See Porst and Sharlip, 2006; 
Saenz de Tejada, 2000; Mills et al., 2001). 
 
Figure 1.7 Relaxation of penile smooth muscle via the NO/cGMP pathway (Porst and 





1.3.2.5  RhoA/Rho-kinase in contractile mechanism 
 
The degree of actin-myosin interaction that is essential for smooth muscle contraction 
depends on the phosphorylation state of MLC. This, in turn depends on two enzymes: 1) the 
Ca
2+
-calmodulin activated MLC kinase which phosphorylates MLC (as discussed in the 
previous section); and 2) the Ca
2+
-independent MLC phosphatase (MLCP) which 
dephosphorylates MLC (Sauzeau et al., 2000). In other words, smooth muscle contraction can 
be mediated in two ways: by increasing the intracellular cytosolic Ca
2+
 and its subsequent 
activation of MLCK or by increasing the Ca
2+
 sensitivity of the contractile apparatus by 
inhibiting the activity of MLCP. Conversely, relaxation of smooth muscle can result from a 
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decrease in cytosolic Ca
2+
 concentration and/or ‘Ca2+-desensitization’ of the contractile 
apparatus (Somlyo and Somlyo, 1994; Somlyo, 1997). 
 
At the cellular level, RhoA/Rho-kinase signalling pathway acts on the MLCP to mediate 
contraction at a constant Ca
2+
 concentration. RhoA is a small monomeric GTPase. In resting 
smooth muscle, most of the RhoA is in the cytosol where it is bound to guanosine 
diphosphate (GDP) and is rendered inactive. When the GDP is converted to GTP, RhoA is 
activated and translocated into the plasma membrane (Gong et al., 1997a). Activated RhoA 
can stimulate Rho-kinase (a serine/threonine kinase), which would then phosphorylate the 
myosin binding subunit (MBS) of MLCP. Phosphorylated MLCP is the inactive form of 
MLCP and therefore, it will promote higher levels of phosphorylated MLC, actin-myosin 
interaction and smooth muscle contraction. On the other hand, inhibition of Rho-kinase helps 
to increase MLC phosphatase activity, MLC dephosphorylation and smooth muscle relaxation 
(Mills et al., 2001). 
 
In the dynamic equilibrium of erectile response, there is evidence that the RhoA-dependent 
Ca
2+
 sensitization/contraction can be inhibited by NO/cGMP/PKG signalling. At the cellular 
level, cGMP through cGMP-dependent protein kinase (cGK) phosphorylates and inhibits the 
activity of RhoA. As further confirmations, sodium nitroprusside (SNP) – an NO donor - is 
found to inhibit the translocation of RhoA to the plasma membrane; a process which is 
required for its activation (Sauzeau et al., 2000) and detumescence. Similarly, the NO-
induced increase in ICP is also shown to be potentiated by prior treatment with Rho-kinase 
inhibitor (Mills et al., 2002).  
 
1.3.3 Cross talk between H2S and NO 
 
Several groups have attempted to elucidate the relationship between H2S and NO but while 
the evidence generally points to the existence of a cross talk between the two 
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gasotransmitters, the exact nature of the interaction is difficult to characterise accurately. On 
one hand, there is evidence that the two gases are synergistic in their actions/effects (Hosoki 
et al., 1997). On the other hand, they can regulate each other’s production (Zhao et al., 2001).  
Some groups reported that H2S can regulate NO production, for example: studies by Kubo 
and co-workers showed that NaHS inhibited all three isoforms of NOS; however this 
inhibition was reversed with increasing concentration of NOS co-factor, BH4 (Kubo et al., 
2007b). The same group also observed that while NaHS inhibited the activity of recombinant 
eNOS, this inhibition was limited to the vasoconstrictor activity of H2S (which occurs at low 
concentration of H2S) because overall, H2S still causes a dose-dependent relaxation of pre-
contracted aortic tissue (Kubo et al., 2007a). Furthermore, H2S can also modulate NOS 
substrate availability by down-regulating the transporter for L-arginine (Geng et al., 2007). 
Interestingly, there are also reports that NO can affect endogenous H2S biosynthesis. 
Exogenous NO has been shown to increase CSE activity, possibly through direct interaction 
with CSE protein which contains 12 cysteines, the potential substrate for nitrosylation (Zhao 
et al., 2001). Additionally, NO may also modulate CSE substrates’ availability, considering 
that NO has been shown to stimulate the uptake of cystine (a known CSE substrate) (Li et al., 
1999). 
 
It therefore, appears that the relationship between the H2S-NO cross talk and its functional 
end result (contraction/relaxation) is complex and context-dependent, possibly because H2S 
may have multiple mechanisms of action. For example, the concentration dependent 
contractile/relaxant activity of H2S may be mediated through different mechanisms or 
modulation of the same mechanism. This means that the difference in the microenvironment 
conferred by different tissue/organ system is likely to be an important factor and results 
pertaining to H2S effects on one organ system may not be readily extrapolated to other organ 
system. Unfortunately, most of the investigations that explore the cross talk between H2S and 
NO were done in the vascular system; there is currently very limited information of this cross 
talk on non-vascular smooth muscle cells, particularly on the penile tissue (which is 
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comprised of both vascular and non-vascular smooth muscles). The cross talk between H2S 
and NO in erectile physiology is of particular interest considering the importance of the NO 




























2. RESEARCH INTEREST AND OBJECTIVES 
 
Research on gasotransmitters is an interesting field because it defies the long standing notion 
that communication between cells has to be limited by intracellular distances and receptor-
ligand interaction. Being gasotransmitters, H2S and NO seem to share a lot of similarities in 
their action. Previous studies done in this lab also show that H2S, like NO, possesses pro-
erectile properties but its mechanism(s) of action is still largely unknown (Srilatha et al., 
2006). 
 
As such, the objectives of this study are to: 
 
1. Verify that H2S is endogenously produced in the animal model  
2. Investigate the effects of H2S on erectile function in vivo using rat models 
3. Investigate the mechanism(s) of facilitatory action of H2S, including: 
 Involvement of the second messenger system cAMP and cGMP 
 Interaction with RhoA/Rho-kinase pathway 
 Hormonal influence 
4. Investigate the interaction between H2S and NO at different points in the pathway, that is: 
 Production of NO 
 Expression of NOS 















Sodium hydrosulphide hydrate (NaHS; H2S donor; Cat # 161527), Nω-Nitro-L-arginine 
methyl ester hydrochloride (L-NAME; non-specific nitric oxide synthase inhibitor; Cat # 
N5751) and DL-propargylglycine (PAG; CSE inhibitor; Cat # P7888) were purchased from 
Sigma Aldrich (St Louis, MO, USA). Testosterone cypionate and sildenafil citrate were 
purchased from Pfizer (Kent, UK). For in vivo treatment, all drugs except testosterone were 
dissolved in water. For in vitro studies using tissue/primary cell culture, NaHS and sildenafil 




All primers were synthesised by Sigma Aldrich. The kit for cGMP and cAMP enzyme 
immunoassay (EIA) was purchased from Cayman chemicals (Cat # 581021 and 581001 
respectively). The medium used was DMEM1152 from Sigma Aldrich which contains L-
glutamine, 4500 mg/L glucose, 25 mM HEPES (4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid) and was supplemented with 3.7 g/L of sodium bicarbonate (US 
Biological Cat # S4000). The chemiluminescent immunoassay kit for testosterone 
measurement was purchased from Siemens.  
 






Items Purchased from Catalogue number 
 
0.5% Trypsin-EDTA Gibco (Invitrogen) #15400 
0.5 M Tris-HCl buffer pH 6.8 Biorad #161-0799 
1.5 M Tris-HCl buffer pH 8.8 Biorad #161-0798 
2-Propanol (Isopropyl alcohol) Sigma Aldrich #I9516 
30% Acrylamide/Bis solution, 29:1 (3.3%C) Biorad #161-0156 
3-Isobutyl-1-methylxanthine (IBMX) Sigma Aldrich #I7018 
Agarose Biorad #161-3102 
Ammonium persulfate (APS) Biorad #161-0700 
Antibiotic:antimycotic solution Gemini Bio-
Products 
#400-101 
Baneocin Sandoz GmbH N.A. 
Baytril Bayer N.A. 
Blocking grade blocker non fat dry milk Biorad #170-6404 
Blue/Orange 6x loading dye Promega #G190A 
Bovine serum albumin (BSA) Sigma Aldrich #A-3311 
Bradford reagent Sigma Aldrich #B6916 
Carprofen (Rimadyl) Pfizer N.A. 
Cell lytic MT solution Sigma Aldrich #C3228 
Chloroform Sigma Aldrich #25668 
DNA ladder 100bp Promega #G210A 
DNA ladder 50bp Promega #G4521 
DNaseI Ambion #AM2222 
DNaseI buffer Ambion #AM8170G 
Ethanol Fisher Scientific #E/0650DF/17 




 Base #BIO-1050 
Flavin adenine dinucleotide disodium salt 
hydrate (FAD) 
Sigma Aldrich #F6625 
Foetal bovine serum (FBS) Gibco (Invitrogen) #10270-106 
Gel red Biotium #41003 
Glycine Biorad #161-0718 
Heparin Hanlim Pharm N.A. 
Immun-Blot PVDF membrane Biorad #162-0177 
Iron (III) chloride (FeCl3) Sigma Aldrich #F7134 
Laemmli sample buffer  Biorad #161-0737 
L-cysteine Sigma Aldrich # 168149 
Membrane protein extraction kit  Promokine # PK-CA577-K268-
50 
Methanol Sigma Aldrich #34860 
Microamp optical 98-well reaction plate Applied Biosystem #4306737 
Mini trans blot filter paper Biorad #1703932 
N-(1-Naphthyl)ethylenediamine dihydrochloride 
(NED) 
Sigma Aldrich #222488 
N,N-dimethyl p-phenylenediamine 
dihydrochloride (NNDPD) 
Sigma Aldrich #D4139 
Nitrate reductase (NAD[P]H) Sigma Aldrich #N7265-10UN 
Phosphate buffered saline (PBS) 1
st
 Base #BUF-2040-10x1L 
Phosphoric acid (H3PO4) Sigma #P5811 
Potassium dihydrogen phosphate (KH2PO4) Merck #4531473410 
Potassium phosphate dibasic trihydrate 
(K2HPO4) 
Sigma Aldrich #P9666 
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Precision plus protein standards Biorad #161-0374 
Prostaglandin E1 (PGE1) Sigma Aldrich #P7527 
Protease inhibitor cocktail Sigma Aldrich #P8340 
Pyridoxal 5′-phosphate hydrate (PLP) Sigma Aldrich #P9255 
RNase docontamination solution (RNaseZap®) Ambion #AM9780 
Sildenafil citrate (Viagra) Pfizer N.A. 
Sodium Azide (NaN3) Fluka Biochemika #25668 
Sodium dodecyl sulphate (SDS) Biorad #161-0301 
Sodium nitrite (NaNO2) Sigma Aldrich #S2252 
Stripping buffer Thermoscientific #21059 
Sulphanilamide Sigma Aldrich #S9251 
Superscript III First strand synthesis system for 
RT-PCR 
Invitrogen #18080-051 
SYBR Green PCR master mix Applied Biosystem #4309155 
Tetramethylethylenediamine (TEMED) Biorad #161-0801 
Transfer buffer  
(25 mM Tris, 192 mM Glycine, 20% methanol) 
Self-reconstituted  N.A. 
Trichloroacetic acid (TCA) Sigma Aldrich #T9159 
Tris Biorad #161-0715  
Tris/Borate/EDTA (TBE) buffer 




(25 mM Tris, pH 8.3; 192 mM Glycine, 0.1% 
SDS) 
Biorad #161-073 
TritonX-100 Biorad #161-0407 
Trizol Invitrogen #15596-026 
Trypan blue solution Sigma Aldrich #T8154 
Tween20 Chemical Reagent #T2008687 
Zinc acetate Sigma Aldrich #383317 
β-Mercaptoethanol Biorad #161-0710 
β-Nicotinamide adenine dinucleotide 2′-
phosphate reduced tetrasodium salt hydrate (β-
NADPH) 
Sigma Aldrich #N1630 
Table 1. List of reagents, chemicals and kits used 
 
 
3.2 Experimental Methods 
 
Young adult (8-9 weeks old) male Sprague-Dawley (SD) rats were obtained from Laboratory 
Animal Centre, National University of Singapore (NUS) and given access to standard rat 
chow and water ad libitum. All experimental procedures involving laboratory animals were 
undertaken in accordance with established International Guiding Principles for Animal 
Research. The followed protocols were also duly approved by Institutional Animal Care and 
Use Committee (IACUC) of NUS.  
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3.2.1 Cell culture 
 
3.2.1.1 Media preparation 
 
The DMEM1152 (as described in section 3.1.2) was reconstituted with 10% FBS and 10 
mL/L of antibiotic-antimycotic solution (containing penicillin G sodium salt, streptomycin 
sulphate and amphotericin B) and sterile-filtered by passing through 0.22 µm filter 
membrane. The prepared medium was then stored at 4°C until use. 
 
3.2.1.2 Isolation of rat erectile tissue 
 
For tissue collection, rat was first euthanised with an overdose of sodium pentobarbital 
euthanasia solution (200 mg/kg) which was administered intraperitonially. The penis was 
excised, and the connective tissue and fat were removed. The tissue was collected in the 
reconstituted DMEM medium and kept in ice. Subsequent steps after tissue collection were 
carried out in the sterile environment of a class II biosafety cabinet, fitted with high efficiency 
particulate air (HEPA) filter. The rat CC culture was prepared using the method by Krall et al. 
(Krall et al., 1988) with some modifications (Carosa et al., 2010; Zhao and Christ, 1995; 
Christ et al., 1992). 
 
3.2.1.3 Primary culture of rat corpus cavernosum smooth muscle 
 
The CC was carefully separated from the fascia, glans penis and tunica albuginea, washed 
thrice in ice-cold sterile PBS, and then transferred to the DMEM medium. It was then cut into 
small strips (approximately 1 mm
3
 in dimension). The explants were cultured in a 75 cm
3
 
tissue culture flask for 4-6 days at 37°C in a fully humidified CO2 incubator (5% CO2 and 
95% O2). When the explants had grown and became attached to the substratum as observed 
under a microscope, additional DMEM was added. Following this stage, the cells would 
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migrate from the explants and undergo proliferation. The medium inside the flask was 
replaced with fresh solution every 4 days. Upon reaching > 90% confluency, the cells were 
either used for experiment or sub-cultured. They were detached by treatment with 0.05% 
trypsin and 0.02% EDTA for 5-10 minutes at 37°C. Once complete detachment was observed, 
equal volume of the medium was added such that the activity of trypsin ceased. The 
suspension was centrifuged at 500 g for 5 minutes, washed in sterile PBS twice and 
resuspended in the reconstituted medium. Manual cell count, to determine the total number of 
cells was carried out with a hemocytometer (triplicate readings were made from each cell 
suspension sample). Trypan blue exclusion test was also carried out simultaneously to 
determine cell viability. The split ratio used for the subculture was adjusted according to the 
cell number such that each 175 cm
2
 flask contained approximately 0.7-0.8 x 10
6
 cells, an 
optimal seeding density required for cell growth.  
 
Only cells with viability of > 90% were used for experiments. In order to preserve corporal 
tissue biology in its physiological state, only cells in the early passages (passage 1-3) were 
used. It was observed that cells from older passages (passage 5 onwards) showed abnormal 
morphology and an obvious decline in viability (< 70%). As confirmed by earlier studies 
elsewhere, cells at passage 1-3 also retain their normal cellular properties (including spindle-
shaped morphology (Christ et al., 1992; Campos de Carvalho et al., 1993), calcium and 
potassium channel function (Christ et al., 1993; Fan et al., 1995; Zhao and Christ, 1995), 
PGE1- and forskolin-induced cAMP formation (Palmer et al., 1994)). 
 
Characterization of rat CC in primary cultures is usually done through immunostaining of α-
actin, which is a specific marker for smooth muscle (Guidone et al., 2002). This has been 
performed in this lab previously and it was established that the followed protocol can 




3.2.1.4 Trypan blue exclusion assay 
 
This test was used to determine the number of viable cells present in a cell suspension. It is 
based on the principle that live cells possess cell membranes that are intact and therefore, are 
able to exclude the trypan blue dye in contrast to dead cells (without intact cell membranes), 
which take up the dye. In this test, a viable cell will appear with a clear cytoplasm when 
observed under a microscope, whereas a non-viable cell will have a blue cytoplasm. After the 
adherent cells were trypsinised and centrifuged, they were resuspended in serum-free DMEM. 
Equal parts of the cell suspension and 0.4% trypan blue solution were mixed. The mixture 
was allowed to incubate for 3 minutes at room temperature and then loaded into a 
hemocytometer for manual counting under a microscope. Stained (non-viable) and unstained 
(viable) cells were counted separately.  
 
Percentage of viable cells = (Number of viable cells/ total number of cells) x 100% 
 
3.2.2 Experimental protocol to investigate the involvement of second messenger cGMP 
and cAMP in H2S action 
 
Rat CC primary cultures at passage 1-3 were used for this component. A total of 0.25 x 10
6
 
cells were plated onto each well on a 6-well-plate in reconstituted DMEM and incubated 
overnight at 37°C. The cells were allowed to grow (attached to the substratum) and reach 
confluence. The medium was removed the following day. The cells were washed in PBS and 
conditioned in plain DMEM for 30 minutes before 250 µM of IBMX (non-specific PDE 
inhibitor) was added to each well to prevent the breakdown of cyclic nucleotides. The cells 
were then treated as detailed in Table 2 below. 
 Treatment Dose Incubation condition 
1 control (vehicle) N.A. 30 minutes; 
37°C; 
5% CO2; 95% O2 
2 NaHS 0.01-10 mM 
3 sildenafil citrate  1-100 µM 




3.2.2.1 Measurement of cGMP and cAMP concentration 
 
At the end of the incubation period, either cGMP or cAMP concentration was measured using 
competitive enzyme immunoassay in accordance with the manufacturer’s (Cayman chemical) 
instruction. This assay is based on the competition between the free cXMP (where cXMP 
represents either cGMP or cAMP) present in the sample/standard with cXMP conjugated with 
acetylcholinesterase (AChE, cXMP tracer) for a limited amount of cXMP-specific rabbit 
antibody (cGMP antiserum) binding sites. The concentration of free cXMP varies while that 
of the tracer is held constant and therefore, the amount of cXMP tracer that binds to the 
antibody would be inversely proportional to the amount of free cXMP present in the samples.  
 
The medium was first removed and the cells were lysed with 0.1 M HCl for 20 minutes at 
room temperature. Upon inspection under microscope that most of the cells had been lysed, 
the cells were scraped. The suspension was mixed with a pipette until it was homogenous and 
then centrifuged at 1000 g for 10 minutes. The supernatant was decanted into a clean test 
tube. The samples were then acetylated (using potassium hydroxide (KOH) and acetic 
anhydride) to enhance the sensitivity of the assay before they were transferred into the 
enzyme-linked immunosorbent assay (ELISA) plates and incubated with the cXMP tracer and 
antiserum for 18 hours at 4°C. The complex formed between the rabbit antibody (cXMP 
antiserum) and cXMP would bind to the anti-rabbit IgG that had been pre-coated on the 
ELISA plates (Figure 3.1). At the end of the incubation period, the plates were emptied and 
washed 5 times with the wash buffer. Ellman‘s reagent was reconstituted and added to each 
well. The mixture was incubated for 60-90 minutes in the dark, in an orbital shaker (IKA® 
KS260basic, Germany). The Ellman’s reagent contained substrates to the enzyme 
cholinesterase. The reaction between AChE and its substrates generated products with a 
distinct yellow colour and strong absorption (optical density) at 412 nm. The colour intensity 
of the product formed was measured using a spectrophotometer (Bio-Tek μQuant, USA) at 
410 nm to determine the concentration of cXMP in the sample. Protein concentration in each 
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sample was quantified using Nanodrop (ND-1000, Nanodrop Technologies). The cGMP 
and/or cAMP concentration in each sample was expressed as pmol per mg of protein. Each 
experiment was carried out in triplicate. The samples were also diluted appropriately (10-20 x 
for cAMP measurement and 2-6 x for cGMP measurement) to ensure that the readings fell 
within the range of the standard curve.  
 
 
Figure 3.1 Schematic diagram of the colorimetric competitive EIA for cGMP 
measurement. The absorbance of the final product is directly proportional to the 
concentration of the bound cGMP tracer and inversely proportional to the concentration of 






3.2.3 Experimental protocol to investigate effects of H2S on erectile function in vivo 
 
Age-matched rats were randomly assigned to 5 groups (n=7 per group), namely: 1) non-
treated control, 2) sildenafil (0.7 mg/kg, oral, daily), 3) NaHS (0.8 mg/kg, ip, daily), 4) L-
NAME (30 mg/kg, oral, daily), 5) PAG group (50 mg/kg, ip, twice-weekly). All treatments 
were administered for 10 weeks (Figure 3.2). The doses for different treatment regimens used 
were selected based on the existing literature, that employed the same drug (Balbinott et al., 
2005; Zhu et al., 2007). At the end of 10 weeks, measurement of intracavernosal pressure and 
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mean arterial pressure (MAP) was done (please refer to section 3.2.3.1 below). The animals 
were then euthanised and the required samples (CC and blood) were collected. The blood was 
collected in a tube containing heparinised saline (250 U/ml of heparin) and centrifuged at 
1500 g at 4°C for 15 minutes (Argmann and Auwerx, 2006). Upon collection, these samples 
(including plasma separated from the blood) were snap-frozen in liquid nitrogen and stored at 









3.2.3.1 Measurement of Intracavernosal pressure  
 
The procedure used for electrical stimulation and measurement of erectile response was a 
modification of the method described by Quinlan (Quinlan et al., 1989) and Dail (Dail et al., 
1989). The rat was anesthetised with intraperitoneal injection of ketamine (75 mg/kg) and 
xylazine (10 mg/ml) mix and placed in supine position on a heating pad set at 37°C to 
maintain the body temperature, as thermoregulation may be compromised in rats under 
anesthesia (Wixson et al., 1987). A longitudinal incision of about 3 cm was made in the neck 
region. The left external jugular vein was cannulated with PE10 tubing, connected to a 
syringe for infusion of drug (supplemental anesthesia where necessary as well as sodium 
pentobarbital for euthanasia at the end of the procedure). Tracheotomy was performed next to 
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assist respiration (Di Loreto, 2009). This is particularly important to prevent hypoxia, as this 
condition has been known to affect the H2S pathway. The trachea was identified around the 
midline of the neck right underneath the muscular tissue. A small orifice was made in the 
trachea in between two cartilaginous rings and the catheter was inserted such that the bevelled 
end headed towards the lungs. The cathether and the trachea were tied together so as to secure 
the cathether in position. The right common carotid artery was cannulated with PE50 tubing, 
which was connected to a pressure transducer (AD Instruments) for measurement of the 
(systemic) MAP. A midline incision was made in the lower abdominal region to pack the 
testicles into the abdomen and dissect the lateroprostatic space to expose the pelvic plexus, 
pelvic nerve and cavernous nerve (Figure 3.3a) (Martinez-Pineiro et al 1994). The penile crus 
was exposed through a transverse perineal incision and separation of the overlying 
ischiocavernous muscle. A 27 G needle was connected through PE10 tubing to the pressure 
transducer. This needle was then inserted into the corpus cavernosum for 
monitoring/measurement of the intracavernosal pressure (Figure 3.3b). Bipolar platinum 
electrodes attached to a Grass Instruments stimulator (Warwick, USA) were hooked to the 
cavernous nerve. The lateral lobe of the prostate was manipulated to create free space 
underneath the cavernous nerve and ensure that its contact with the electrode was isolated. 
The following stimulatory parameters were used: 2 V at frequency of 20 Hz for 30-45 s 
(Srilatha and Adaikan, 2006),
 
as they were found to give the most optimal response. All the 
needles and syringes used in this procedure were filled with heparinised saline to prevent 
blood clot formation and prior to each experiment, the pressure transducers were calibrated 
with a mercury manometer. The magnitude of erectile response was expressed as ICP 
normalised to MAP (considering that different drugs affect blood pressure differently, 
ICP/MAP ratio constitutes a more objective parameter to measure erectile response than ICP 
alone; this ratio has been used by other groups and is well recognised as a surrogate marker of 



















3.2.4 Experimental protocol to investigate effects of H2S on biochemical parameters in 
vivo 
 
3.2.4.1 Measurement of H2S production (CBS/CSE activity) in corpus cavernosum 
 
The H2S-synthesizing activity in the corpus cavernosum was measured by the modified 
method of Stipanuk and Beck (Stipanuk and Beck, 1982). In this assay, the tissue was 
supplied with the substrate and co-factors for the enzyme CBS/CSE. Any H2S released by the 
tissue was quantified and the rate of production of H2S was taken as a measure of CBS/CSE 
activity in the tissue. The test sample, 0.1 g of the corpus cavernosum tissue was thawed and 
homogenised (Ultra-turrax, IKA® T10 basic) in 2 ml of 100 mM ice cold phosphate buffer 
(KHPO4; pH 7.4). This buffer was prepared by mixing 100 mM K2HPO4 solution with 100 
mM KH2PO4 solution in the ratio of 10:3 to achieve the correct pH. The tissue homogenate 
was centrifuged at 19000 g for 30 min at 4°C and the supernatant obtained was assayed. To 
430 µl of the homogenate, 30 µl saline, 20 µl of 0.05 M PLP (final concentration in 500 µl 
reaction mixture: 2 mM) and 20 µl of 0.25 M L-cysteine (final concentration: 10 mM) were 
added sequentially in a vial (that was tightly sealed with a double layer of parafilm) and 
placed in ice until the reaction was initiated by transferring the vial containing the reaction 
mixture from ice to a water bath set at 37°C. The vial was left in the water bath for 30 
minutes. Zinc acetate (1%, 250 μl) was then added to trap the evolved H2S followed by 
treatment with TCA (10%, 250 µl) to stop the reaction. Subsequently, 133 µl of 20 mM 
NNDPD in 7.2 M hydrochloric acid (HCl) and 133 µl of 30 mM FeCl3 in 1.2 M HCl were 
added sequentially and the absorbance of the resulting solution was measured 
spectrophotometrically at 670 nm, using a 96-well microplate reader (Bio-Tek μQuant, USA). 
As a control, 430 µl phosphate buffer was used in place of the tissue homogenate. All samples 
were assayed in duplicate.  The H2S concentration in the sample was calculated against a 
standard calibration curve of NaHS (3.125–250 μM) and the results were expressed as µmol 
of H2S formed per gram of protein per hour. The protein concentration in each sample was 
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determined using nanodrop (ND-1000, Nanodrop Technologies). The calibration curve was 
prepared on the same day of sample processing. 
 
3.2.4.2 Measurement of plasma H2S concentration  
 
The H2S concentration in the plasma was assayed as described by Mok and co-workers (Mok 
et al., 2004). The samples were centrifuged at 3000 rpm for 5 minutes after thawing and 100 
µl of the plasma was added to a tube filled with 0.25 ml of 1% zinc acetate followed by 
addition of 400 µl of distilled water. The H2S present in the sample will be chemiadsorbed by 
zinc acetate and transformed into stable zinc sulphide, which can then be recovered by 
extraction with water. To this, 133 µl of NNDPD in 7.2 M HCl and 133 µl of FeCl3 in 1.2 M 
HCl were added sequentially and the final reaction mixture was allowed to incubate for 10 
minutes at room temperature. In presence of FeCl3 in a strongly acidic condition, the extracted 
sulphide reacts with NNDPD to yield methylene blue. At the end of the incubation period, 
0.25 ml of 10% TCA was added to deproteinate the samples. The reaction mixture was then 
centrifuged at 19000 g for 5 minutes at 4°C and decanted into a 96-well plate where its 
absorbance was measured at 670 nm using a microplate reader (Bio-Tek μQuant, USA). All 
plasma samples were assayed in duplicate. The concentration of H2S was calculated against a 
calibration standard curve of NaHS (3.125–250 μM). 
 
3.2.4.3 Measurement of NO concentration in plasma and corpus cavernosum 
 
In physiological condition, NO is rapidly oxidised into nitrate and nitrite (which constitute 
stable end products of NO metabolism) and these were measured by the assay protocol. This 
was then taken as a reflection of endogenous synthesis of NO (Li et al., 2009b). The assay 
was performed according to the method described by Green and co-workers with some 
modification (Green et al., 1982). Plasma samples were diluted 5 times with 100 mM 
phosphate buffer (pH 7.4), while CC homogenates were used undiluted for this experiment. 
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The diluted plasma/CC homogenate (80 µl) was incubated in 20 µl of enzyme/co-factor 
mastermix (comprising of 250 µl of 0.1 mM FAD, 250 µl of 2 mM β-NADPH and 500 µl of 2 
U/ml nitrate reductase (NR) enzyme) for 30 minutes at 37°C and protected from light. The 
NR used, assisted with its co-factors β-NADPH and FAD, will reduce nitrate in the samples 
to nitrite. Griess reagent (100 µl of solution containing an equal volume of 0.2% w/v NED in 
5% H3PO4 and 2% w/v sulphanilamide in 5% H3PO4; the two parts mixed within 12 hours of 
use and kept chilled) was added and the mixture was incubated for 15 minutes at 37°C. The 
nitrites in the reaction mixture (including nitrites present in the sample and nitrites derived 
from nitrates by NR) will react with the Griess reagent to form Griess chromophore (purple 
azo dye) whose absorbance can be measured with a spectrophotometer (Bio-Tek μQuant) at 
540 nm. The nitrite concentration was calculated from a standard curve of NaNO2 (0-87.5 
µM). 
 
3.2.5 Experimental protocol to investigate effects of H2S on expression of targeted 
mRNAs in vitro 
 
Rat CC was first isolated, cut into small strips (approximately 1 mm
3
 in dimension) and 
placed in a 24-well plate in serum-free DMEM. The rat CC was treated as follows: 1) medium 
control, and 2) NaHS (0.1, 0.5, 1, 2 and 10 mM). The drug was diluted in serum-free DMEM. 
The tissue was treated with NaHS for 6 hours at 37°C in a CO2 incubator. 
 
3.2.5.1 Extraction of total RNA from rat corpus cavernosum 
 
About 50-60 mg of rat CC was mixed with 1 ml of Trizol (Invitrogen) and homogenised 
(Ultra-turrax, IKA® T10 basic) in ice. The tissue homogenate was centrifuged at 12000 g for 
10 minutes at 4°C to remove insoluble materials (e.g. proteins, fats, polysaccharides and 
extracellular materials). This supernatant was then decanted into a fresh RNase-free tube and 
incubated at room temperature for 5 minutes to allow for the complete dissociation of 
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nucleoprotein complexes. Then, 0.2 ml of chloroform was added to the homogenate per ml of 
Trizol used. The tube was tightly capped, shaken vigorously for 15 seconds and incubated at 
room temperature for 2-3 minutes. The mixture was centrifuged at 12000 g for 15 minutes at 
4°C. After centrifugation, the mixture separates into 3 phases: a lower red phenol-chloroform 
phase, an interphase and a colourless upper aqueous phase. The RNA will remain exclusively 
in the upper aqueous phase. This phase was transferred to another fresh RNAse-free tube. 
About 0.5 ml of isopropyl alcohol was added (per 1 ml of Trizol used) to precipitate the RNA 
from the aqueous phase. The mixture was allowed to incubate for 10 minutes at room 
temperature and then centrifuged at 12000 g for 10 minutes at 4°C. The supernatant was 
removed and the RNA pellet was washed with 1 ml of 75% ethanol (dissolved in 
diethylpyrocarbonate (DEPC) -treated water). The sample was mixed by vortexing and 
centrifugation at 7500 g for 5 minutes at 4°C. At the end of the procedure, the RNA pellet 
was air-dried for 5-10 minutes and dissolved in 100 µl of DEPC-treated water. The RNA 
solution was incubated at 55°C for 10 minutes to ensure complete dissolution. The RNA 
obtained was then stored at -70°C until it was used. 
 
Disposable gloves and mask were worn at all times throughout the procedure to prevent 
introduction of RNase into the sample. Similarly, disposable and filtered pipette tips and 
RNAse-free tubes were used during the RNA isolation. Laboratory bench tops, 
glassware/plasticware and equipments used (pipettes) were treated with RNase 
decontamination solution (RNase Zap®) before the start of the experiment and periodically 
throughout the procedure. Total RNA isolated was quantified using a nanodrop machine (ND-
1000, Nanodrop Technologies) by measuring its absorbance at 260 nm.  
 
Nanodrop was also used to obtain the A260/A280 ratio of each RNA sample. This ratio is used 
to assess the purity of an RNA preparation (RNA samples with A260/A280 ratio > 1.8 suggest 
minimum protein contamination). To assess the integrity of the RNA samples, the samples 
were run on 1% agarose gel with TBE buffer at 100 V for 30-40 minutes. The presence of 
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sharp 28S and 18S rRNA bands (with intensity in the ratio of 2:1) and absence of low 
molecular weight smear would indicate relatively intact RNA samples with little degradation. 
Only intact RNA samples were used for experiments. 
 
3.2.6 Reverse transcription of RNA to cDNA 
 
The RNA samples were first treated with DNase I to degrade any contaminating genomic 
DNA template. The DNase I was then heat-inactivated at 75°C for 10 minutes in presence of 
4 mM EDTA. The RNA samples (5 µg) was added to RNase-free tube containing 3 µl of 50 
µM oligo(dT) primers and 3 µl of 10 mM dNTPs. This RNA/primer mixture was incubated at 
65°C for 5 minutes in a thermocycler (ThermoHybaid) and placed on ice. An enzyme 
mastermix comprising of 12 µl of 25 mM MgCl2, 6 µl of 0.1 M DTT, 3 µl RNase OUT 
enzyme and 3 µl of Superscript III enzyme was added to the RNA/primer mix according to 
manufacturer’s instruction. The resulting mixture was incubated at 50°C for 50 minutes and at 
85°C for 5 minutes in the thermocycler. After the first strand synthesis was completed, 3µl of 
RNaseH was added to remove the RNA templates. The resulting cDNA samples were stored 
at -20°C until they were used. 
 
3.2.7 Real Time (Quantitative) RT-PCR 
 
Real time PCR/ qPCR analysis was performed in duplicate or triplicate in a thermal cycler 
(ABI Prism® 7000 Sequence Detection System, Applied Biosystems, USA) set to the 
following thermal cycling parameters: Taq activation at 95°C for 10 minutes, 50 cycles of 
denaturation at 95°C for 15 s and combined annealing and extension step at 60°C for 1 









cDNA template 2 µl 
Forward Primer (5 µM) 1 µl 
Reverse Primer (5 µM) 1 µl 
SYBR Green Master mix (2X) 10 µl 
DEPC-treated H2O 6 µl 
Total : 20 µl 
Table 3a. Real time RT-PCR mixture 
 







eNOS (F) 5’-CAG CAC CAG ACC 
ACA GCC CC-3’ 
(R) 5’- TCC TGC TGA GCC 





sGCα1 (F) 5’- ACA CAA TAT GCA 
TCT CCG ATG G-3’ 
(R) 5-‘ GCT CTC TAT ACT 






sGCβ1 (F) 5’- CCC GTG GAA ACT 
GAT GTC AA-3’ 
(R) 5’- CGG GAC CTA GTA 






RhoA (F) 5’-AAG GAC CAG TTC 
CCA GAG GT-3’ 
(R) 5’-TGT CCA GCT GTG 







(F) 5’-TTT CGG ATT CAA 
CTA GTG TTG C-3’ 









(F)5'-GCA CAT GTA TGA 
AAA TGG ATG AAA C-3' 
(R)5'- CAT AAT TTT GCT 






β-Actin (F)5’- GGT CCA CAC CCG 
CCA CCA GTT-3’ 
(R) 5’-ACC CAT ACC CAC 






Table 3b. Primer sequences for each gene of interest, including eNOS, sGCα1, sGCβ1, 







The SYBR Green Master mix contains SYBR Green I Dye, AmpliTaq Gold® DNA 
polymerase, dNTPs with dUTP, Passive Reference, and optimised buffer components. The 
mixture was loaded into a MicroAmp Optical 96-well reaction plate (Applied Biosystems Cat 
#4306737) and sealed with an optical adhesive cover (Applied Biosystems Cat # 4311971). 
No template control (NTC) was run together with the samples in each PCR reaction (NTC 
contains DEPC-treated H2O in place of the cDNA template) in triplicate to check for any 
contamination in the master mix and/or primer dimer formation. The primers for eNOS and β-
actin bridge at least 1 intron, thereby minimizing further the chance of any contaminating 
genomic DNA being amplified in the PCR reaction.  
 
Relative quantitative values (RQ) were calculated based on the difference in threshold cycle 
number (Ct) between different samples. The fold change in mRNA expression was calculated 
using the ΔΔCt method. The measurement of target genes in all samples was normalised to 
the housekeeping gene β-actin. Data was presented as fold change in expression (as 
determined by RQ values) in treated groups, relative to control sample. 
 
Since SYBR green non-specifically binds to dsDNA, it is not possible to identify the PCR 
product from the fluorescent signal alone. To verify that the primers used were specific, the 
products from the real time PCR were run and visualised on an agarose gel. The size of each 
amplicon was compared to the expected product size of each PCR reaction as calculated in 
Table 3b. Primers which produced a single band PCR product at the correct size were 
considered specific. Dissociation curve (melting curve) analysis was also performed at the 
end of the real time PCR. Any non-specific product amplified in the PCR reaction and/or any 
primer dimers would show up in this analysis as a separate peak that is distinct from the 
desired amplicon peak. Primers which produced only a single distinct peak in the dissociation 
curve analysis were considered specific. Only primers which produced specific products were 
chosen for the purpose of experiments. 
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3.2.8 Experimental protocol to investigate the effects of H2S on expression of target 
proteins in vitro 
 
To investigate the effects of H2S on the expression of different proteins in vitro, both dose-
response and time-response studies were carried out. Rat CC was first isolated, cut into small 
strips (approximately 1 mm
3
 in dimension) and placed in a 24-well plate in serum-free 
DMEM. The NaHS was dissolved in DMEM and added to each well. Incubation was done at 
37°C in a CO2 incubator.  
 
3.2.8.1 Protein extraction from rat corpus cavernosum tissue 
 
Cell lysis buffer was prepared by mixing 50 µl (0.5%) of protease inhibitor cocktail (Sigma 
Aldrich, St Louis, MO) to 10 ml of cell lytic mammalian tissue buffer (Sigma Aldrich, St 
Louis, MO). About 100 mg of the rat CC tissue was homogenised (Ultra-turrax, IKA® T10 
basic) in 1 ml of the cell lysis preparation on ice. The homogenate was centrifuged at 14000 g 
at 4°C for 10 minutes and the supernatant transferred to a fresh tube. The protein samples 
were stored at -80°C until further use.  
 
3.2.8.2 Isolation of cytoplasmic and total membrane protein 
 
Extraction of cytoplasmic and total membrane protein was done using a membrane protein 
extraction kit (Promokine, Heidelberg, Germany). About 100 mg of rat CC tissue was 
homogenised (Ultra-turrax, IKA® T10 basic) in 350 µl of lysis buffer (containing 0.2% 
protease inhibitor cocktail). The homogenate was then transferred to a 1.5 ml tube and 
centrifuged at 700 g at 4°C for 10 minutes. The supernatant was decanted to a fresh tube and 
centrifuged again as above; this process was repeated until no pellet was seen after 
centrifugation. The resulting supernatant was centrifuged at 10000 g at 4°C for 30 minutes. 
The supernatant contained cytosolic proteins while the pellet contained total cellular 
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membrane protein (TMP) - comprising proteins originating from both plasma membrane and 
cellular organelle membrane. The TMP pellet was dissolved in 50 µl of PBS with 0.5% 
TritonX-100. The samples were stored at -80°C until analysis. Protein quantification was 
done using the Bradford assay (Biorad, CA, USA) and by measuring its absorbance at 280 nm 
using a spectrophotometer (ND-1000, Nanodrop Technologies). 
 
3.2.8.3 Western blot 
 
About 15-30 µg of protein samples were mixed with the sample buffer (Laemmli buffer 
containing 5% β-mercaptoethanol, which was freshly prepared on the day of sample run), 
boiled at 96°C for 5 minutes and loaded into 10% sodium dodecyl sulphate-polyacrylamide 
gel electrophoresis (SDS-PAGE). Electrophoresis was performed at 80 V for 20-25 minutes 
(through the stacking gel) and then at 120 V for 75-85 minutes (through the resolving gel). 
The proteins were subsequently transferred from the gels to PVDF membranes with the 
following transfer condition: 100 V for 90-100 minutes at 4°C with constant stirring. The 
membranes were then blocked with 5% blocking grade non fat dry milk in PBS containing 
0.1% Tween20 (PBST) at room temperatures for 60 minutes. After blocking, the PVDF 
membranes were incubated with their respective primary antibodies as listed in Table 4. Pan 
actin (which represented all isoforms of/total actin) was used as loading control. The primary 
antibodies were incubated at 4°C overnight in an orbital shaker (IKA® KS260basic, 
Germany). The membranes were then washed in PBST and incubated with their respective 
horseradish peroxidase (HRP)-conjugated secondary antibodies (please refer to Table 4) for 
1.5 hours. The membranes were then washed again in PBST. Protein bands were visualised 
by the addition of enhanced chemiluminescent (ECL) substrates for HRP (SuperSignal® 
West Pico Chemiluminescent Substrate, Pierce) and captured by exposure to film 
(Thermoscientific Pierce Cat # 0034089). Protein was quantified by measuring band area and 
intensities in the film using Image J software. The results were expressed as fold difference in 






























1: 1000 Rabbit; 
polyclonal 






1: 200 Mouse; 
monoclonal 
1:1000 ~24 Bivalacqua 
et al., 2004; 







1: 300 Mouse; 
monoclonal 
1:1000 ~180 Bivalacqua 
et al., 2004; 
Wang et al., 







1: 5000 Mouse; 
monoclonal 
1: 10000 ~42 Poling et 
al., 2011 
Table 4. Antibody information (primary and secondary) and the conditions used in 




3.2.9 Experimental protocol to investigate the involvement of testosterone in H2S’ effects 
 
Age-matched rats were randomly assigned to 6 groups (n=7 per group) as follows: 1) normal 
control, 2) normal NaHS (0.8 mg/kg, ip, daily), 3) normal testosterone (10 mg/kg, im, twice 
weekly), 4) castrated control, 5) castrated NaHS (0.8 mg/kg, ip, daily), 6) castrated 
testosterone (10 mg/kg, im, twice weekly). The NaHS was dissolved in distilled H2O just 
prior to administration. All treatments were continued for 10 weeks. At the end of the 
treatment, changes in the rats’ intracavernosal pressure to electrical stimulation were 
measured (as in section 3.2.3.1). The rats were then euthanised and their plasma collected and 






3.2.9.1 Castration procedure in rat model 
 
Total (closed) orchiectomy of the rat was performed under isoflurane anesthesia by standard 
procedure (Dulisch, 1976). Throughout the surgical procedure, the rat was placed in a heating 
pad set at 37°C to minimise heat loss, and its heart rate and oxygen level in the blood were 
closely monitored with a pulse oxymeter. The hair over the inguinal area was removed and 
the skin area was disinfected with 70% alcohol and iodine solution. The testicle was 
massaged out of the abdominal cavity into the scrotum and held in position. The inguinal skin 
was carefully incised and the testicle was pulled out through this small incision without 
opening the tunica vaginalis. The spermatic cord and blood vessels were identified and 
clamped with a mosquito hemostat. They were then ligated proximal to the clamp with an 
absorbable suture and excised. After the haemostat was released, the stump was held with a 
pair of forceps distal to the ligature and visual inspection was done to ensure absence of 
hemorrhage. The skin incision was finally closed with non-absorbable suture. The procedure 
was repeated on the opposite side to remove the other testis. Antibiotic (Baytril; 5 mg/kg) and 
painkiller (Carprofen; 5 mg/kg) were administered intramuscularly at the end of the surgery 
and continued for 5 consecutive days post-surgery. Broad spectrum antibiotic powder 
(Baneocin) was also applied topically daily until the wound healed completely. A recovery 
period of 4 weeks was allowed before starting the study. 
 
3.2.9.2 Measurement of testosterone concentration 
 
Testosterone concentration was measured using Immulite1000 analyzer (Siemens, USA) 
(Friedrich et al., 2008). The process was an automated solid-phase competitive 
chemiluminescent enzyme immunoassay. This assay was based on competitive binding 
between labelled (testosterone conjugated with alkaline phosphatase; this is referred to as 
‘reagent wedge’ in the kit) and non-labelled free testosterone in the samples for a limited 
testosterone antibody binding site (in the form of solid phase ‘test unit’ which contains a 
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polystyrene bead coated with polyclonal rabbit anti testosterone antibody). The analyzer was 
calibrated using adjustors which are vials of 4 ml each of testosterone in high and low 
concentration. The plasma sample (100 µl) was placed in the cup holder, which was loaded 
into the analyzer. The wedge and chemiluminescent substrate were also loaded inside the 
analyzer before running the test. The analyzer would introduce the sample along with the 
labelled testosterone into the reaction tube containing the bead and incubate them for 60 
minutes at 37°C with intermittent agitation. The unbound labelled testosterone and unbound 
samples were removed by centrifugal wash. The analyzer would then add the 
chemiluminescent substrate and let the reaction tube incubate for 5 minutes at 37°C. The 
substrate undergoes hydrolysis in the presence of alkaline phosphatase and emits light. This 
light signal/photon count would be measured by the photomultiplier tube (PTM) and 
converted to analyte concentrations (doses) using stored master curves. The amount of bound 
labelled testosterone was determined and was inversely proportional to the amount of non-
labelled/free testosterone present in the samples. The overall concentration of the testosterone 
in the sample was then calculated and generated by the analyzer. 
 
3.2.10 Statistical analysis  
 
All data were expressed as mean ± standard error of mean (SEM). Statistical evaluation was 
done using t-test for significant differences in mean values for a variety of variables between 
pairs of groups. One-tailed t-test was used when the hypothesis was tested in one direction 
(Ho: µ 1<µ2 or Ho: µ1>µ2) whereas two-tailed t-test was used for testing the hypothesis in 
both directions (Ho: µ1≠µ2).  One-way ANOVA followed by Bon ferroni’s test was used for 
multiple comparisons across groups. All statistical calculations were done using SPSS 







4.  RESULTS  
 
 
4.1 Effects of treatments in vivo 
 
The average body weight of the rats before treatment was in the range of 328.5 ± 5.4 g – 
391.4 ± 4.5 g. The percentage body weight change at the end of the treatment period (10 
weeks) was 178%, 136%, 153%, 132% and 127% for the control, sildenafil, NaHS, L-NAME 
and PAG group respectively. This percentage change was significantly less (p <0.05) in all 
the treatment groups compared to control. 
 
Rat erectile function was assessed at the end of the 10-week period by evaluating the changes 
in intracavernosal pressure to electrical stimulation. In the physiological system, without full 
penile tumescence and the blocking of venous return, ICP will not elevate maximally. Hence, 
any increase in ICP is an indicator of the entry of arterial blood into the CC and the 
appropriate venous blockage, taken as an equivalent of physiological erection. ICP has been 
found to be a suitable experimental index for the evaluation of penile erection in the rat model 
(Chen et al., 1992). For the net change in ICP, the peak reading during electrical stimulation 
was compared as a function of the basal reading before stimulation. For each animal whose 
ICP was measured, its respective MAP was also measured. In the control group, the MAP was 
116 ± 4.7 mmHg. There were no significant differences in MAP in sildenafil and PAG-treated 
group compared to control (Figure 4.1). NaHS however exhibited marked hypotensive effect, 
decreasing the MAP to 95.7 ± 6.8 mmHg while L-NAME pre-treatment caused an increase in 







Figure 4.1 Effects of treatments on magnitude of erectile response to electrical 
stimulation. Measurement was done in vivo on ketamine/xylazine-anaesthetised Sprague 
Dawley (SD) rats at the end of a 10-week long treatment period. (A) Changes in ICP and 
mean arterial pressure (MAP); (B) changes in ICP after normalizing it to the mean arterial 
pressure (ICP/MAP ratio). Each bar represents the mean ± SEM of measurements from 7 
animals. * P-value < 0.05 (increase/decrease). L-NAME = Nω-Nitro-L-arginine methyl ester 
hydrochloride; PAG = DL-propargylglycine; NaHS = sodium hydrosulphide 
 
The NaHS treatment was found to augment the rise in ICP to electrical stimulation at the 
stipulated parameter, as evidenced from the higher ICP/MAP ratio of 0.52 ± 0.03 compared to 
0.36 ± 0.02 in the control group (P < 0.05). However, PAG did not appear to decrease the 












0.02 in control; P > 0.05) after normalizing the ICP to MAP even though PAG caused 
reduction in ICP alone (Figure 4.1). As expected, sildenafil pre-treatment improved the 
magnitude of erectile response to 0.44 ± 0.01 in marked contrast to L-NAME treatment which 
significantly reduced erectile response, compared to control (ICP/MAP of to 0.22 ± 0.01 and 




4.2 Effects of treatments on NO level in plasma and corpus cavernosum in vivo 
 
It was observed that NaHS had a systemic effect on the NO/cGMP pathway when 
administered in the long term, as indicated by the measurement of plasma NO. Treatment 
with NaHS significantly (P < 0.05) increased the plasma NO to 23.0 ± 1.15 µM; an elevation 
of approximately 47% compared to the control group (15.7 ± 0.88 µM) (Figure 4.2). This was 
comparable to sildenafil pre-treatment, which increased the plasma NO by 58% (15.7 ± 0.88 
and 24.9 ± 2.24 µM in the control and sildenafil group respectively). Conversely, PAG 
reduced the plasma NO by 22%. This reduction was significant (P < 0.05) and comparable to 
L-NAME which lowered the plasma NO by 26%. 
 
A similar effect of NaHS and sildenafil was also observed locally; NaHS treatment increased 
the NO concentration in the cavernosum dramatically (from 3.6 ± 0.36 to 6.3 ± 0.85 µmol/g 
protein; a 73.4% increase) whereas sildenafil increased the corpus cavernosum NO level by 
38% (from 3.6 ± 0.36 to 5.0 ± 0.70 µmol/g). It was observed that L-NAME reduced the NO 
level in CC by 9% although this decrease was not statistically significant. Interestingly, PAG 






Figure 4.2 Effects of chronic in vivo treatments of sildenafil, NaHS, L-NAME and PAG 
on nitric oxide concentration in (A) plasma and (B) corpus cavernosum. Each bar 
represents the mean ± SEM of measurements from 7 animals. * P-value < 0.05; ** P value < 
0.005 (increase/decrease). L-NAME = Nω-Nitro-L-arginine methyl ester hydrochloride; PAG 
















4.3 Effects of treatments on H2S level in plasma and H2S production in corpus 
cavernosum in vivo 
 
In vivo treatment with NaHS not only elevated H2S concentration in the plasma (from 24.7 ± 
1.07 to 32.6 ± 1.63 µM; an approximately 31% increase), but it also increased the H2S-
producing capacity in CC from the basal level of 4.4 ± 0.33 µmol/g/hr in the control group to 
7.3 ± 0.75 µmol/g/hr; this represents a 64% increase in the tissue’s H2S-synthesizing capacity 
(Figure 4.3). It was observed that PAG treatment in vivo had no effects on both H2S level in 
plasma as well as H2S production in CC. Rats treated with sildenafil also did not show any 
changes in the plasma H2S level and H2S production in CC. On the other hand, L-NAME-
treated group exhibited a significantly elevated plasma H2S concentration of 42.5 ± 3.06 µM 
compared to control (24.7 ± 1.07 µM); 71% higher level compared to control. However L-










Figure 4.3 Effects of chronic in vivo treatments of sildenafil, NaHS, L-NAME and PAG 
on (A) hydrogen sulphide concentration in plasma and (B) hydrogen sulphide 
production in corpus cavernosum. Each bar represents the mean ± SEM of measurements 
from 7 animals. * P-value < 0.001 (increase). L-NAME = Nω-Nitro-L-arginine methyl ester 
hydrochloride; PAG = DL-propargylglycine; NaHS = sodium hydrosulphide 
 
 
4.4 Effects of NaHS on cGMP and cAMP level in vitro 
 
Cyclic GMP level was measured from the lysate of rat CC primary culture in vitro. It was 
observed that NaHS caused a dose dependent elevation in the level of cGMP (Figure 4.4). 
The concentration of cGMP was raised from 0.11 ± 0.01 pmol/mg in the medium control 
group to as high as 0.30 ± 0.06 pmol/mg with 10 mM of NaHS. Unlike with cGMP, the effect 
of NaHS on cAMP level appeared to be more dose-sensitive with a dose of 1 mM 
significantly increasing the cAMP level from 5.0 ± 0.33 in the medium control group to 7.0 ± 
0.61 pmol/mg. Despite the trend, the effect on cAMP level observed with other doses of 
NaHS used in the study, failed to reach statistical significance (Figure 4.5). For the treatment 
group, NaHS dose higher than 10 mM was excluded as it was supraphysiological and 






The cGMP level in the CC was about 50 fold lower than cAMP level per mg protein but 
despite this low basal (control) level, NaHS was able to significantly increase the cGMP 
concentration. In terms of percentage of change, the maximum increase in cGMP level that 
was induced by NaHS was more dramatic (171.8 % change) than cAMP (38.7 %).  
 
 
Figure 4.4 Effects of 30 minutes incubation of NaHS at indicated dosage on cGMP 
concentration in primary culture of rat corpus cavernosum at passage 1-3. Data shown 
are the mean ± SEM (n= 10). * P-value < 0.05 (increase). 
 
Figure 4.5 Effects of 30 minutes incubation of NaHS at indicated dosage on cAMP 
concentration in primary culture of rat corpus cavernosum at passage 1-3. Data shown 






4.5 RNA samples 
The purity and integrity of the total RNA extracted from the CC were first determined before 
reverse transcription was performed. The RNA samples were still relatively intact after the 
Trizol extraction procedure (result not shown). Some degradation was evident as low 
molecular weight smear but the 28S and 18S rRNA bands were visible and still relatively 
sharp. All the RNA samples were found to have A260/A280 ratio of 1.99-2.00, indicating little/ 
no protein contamination.  
 
4.6 Gene expression of eNOS 
The eNOS and β-Actin primers produced specific products. Only a single band was observed 
for both eNOS and β-Actin, at 121 bp and 169 bp respectively which was the expected PCR 
product size. In both cases, the NTC showed little/no amplification and the dissociation curve 
showed only one peak, indicating that the primers were relatively specific. β-Actin was used 
as internal control throughout our study.  
 
As mentioned in Section 3.1.1, NaHS was dissolved in DMEM. However, comparison of 
eNOS mRNA expression between non-treated CC tissue and CC treated with medium 
revealed that DMEM could affect eNOS expression in the CC tissue samples (result not 
shown). Therefore, medium control (at the longest incubation period used i.e. 6 hours) was 
used for comparison in this study. It was shown that NaHS treatment significantly increased 
the eNOS mRNA level (by almost four fold), when compared to the medium control. This 
effect of NaHS appeared to be time dependent, with the increase being most prominent at 6 
hours (Figure 4.6). The number of experiments that could be carried out was limited by the 






Figure 4.6 Relative expression of eNOS mRNA in rat CC after NaHS treatment at 
different time points as assessed by real time PCR.  Results, normalised to β-actin mRNA, 
are expressed relative to the medium control taken as 1. Data shown are the mean ± SEM 
(n=3). * P < 0.05 (increase). 
 
 
4.7 Gene and protein expression of sGCα1 and sGCβ1 
 
The sGCα1 and sGCβ1 primers both produced specific PCR products. Only one band was 
observed for both sGCα1 and sGCβ1 at approximately 80 bp and 129 bp respectively, which 
corresponded to the expected amplicon size (results not shown). Dissociation curve analysis 
on the real time PCR product revealed a single peak when these primers were used, 
confirming that only one specific product was formed. NTC also showed no amplifications. 
These observations suggest that the primers used here were specific enough for SYBR-based 
qPCR. 
 
Generally, NaHS caused a dose dependent increase in the expression of sGCα1 mRNA in 
vitro. This increase was most apparent at 10 mM dose with more than two fold increase in the 






Figure 4.7 Relative expression of sGCα1 mRNA in rat CC as assessed by real time PCR. 
Effects of different doses (indicated on the x-axis) of NaHS when incubated for 6 hours. 
Results, normalised to β-actin mRNA, are expressed relative to the medium control taken as 
1. Data shown are the mean ± SEM (n=4). * P < 0.005 (increase). 
 
The protein expression of sGCα1 is shown in Figure 4.8a-b. It was observed that the trend of 
sGCα1 protein expression did not really correspond to its mRNA expression. NaHS increased 
the protein expression of sGCα1 in the cellular membrane (to 1.3 fold compared to control) 
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Figure 4.8a sGCα1 protein expression in rat corpus cavernosum (TMP) in control and 
NaHS treated group. Results are expressed in relative densitometric unit (d.u) as a 
percentage of medium control level, after normalizing to loading control pan actin. Data 
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Figure 4.8b sGCα1 protein expression in rat corpus cavernosum (cytosolic fraction) in 
control and NaHS treated group. Results are expressed in relative densitometric unit (d.u) 
as a percentage of medium control level, after normalizing to loading control pan actin. Data 
shown are mean ± SEM (n=4-5). * P < 0.005 (decrease).  
 
 
Similar to its effect on sGCα1, NaHS also increased the expression of sGCβ1 mRNA (Figure 
4.9). The increase in mRNA expression was more prominent for sGCβ1 than sGCα1 for the 
same dose of NaHS used; in particular, 10 mM of NaHS increased the sGCβ1 mRNA 
expression in the CC by five fold whereas the same dose of NaHS only increased the sGCα1 







Figure 4.9 Relative expression of sGCβ1 mRNA in rat CC as assessed by real time PCR. 
Effects of different doses (indicated on the x-axis) of NaHS when incubated for 6 hours. 
Results, normalised to β-actin mRNA, are expressed relative to the medium control taken as 





Figure 4.10 Temporal expression of sGCβ1 protein in rat corpus cavernosum (total 
tissue lysate). Rat CC were treated with 10 mM of NaHS with different incubation period. 
NC= no treatment control; MC= medium control. 
 
Study of the temporal expression of sGCβ1 at the protein level using western blot revealed 
that DMEM inhibited the expression of sGCβ1 protein (Figure 4.10) therefore subsequent 
studies on sGCβ1 expression used medium control (MC) for comparison. Treatment with 10 
mM of NaHS significantly increased the sGCβ1 protein expression (compared to MC as 
baseline) at all the time points used. This result was consistent with the qPCR data since at 
this dose NaHS also increased the sGCβ1 mRNA level considerably. 
NaHS 10mM 
Hour NC MC 4 12 6 9 
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Generally, NaHS increased the expression of both membrane-associated and cytosolic sGCβ1 
protein in a dose dependent manner (Figure 4.11). Noticeably, only NaHS in the higher mM 
range (1-10 mM) significantly increased the protein expression of sGCβ1. At this dose range, 
approximately three-fold increase in sGCβ1 protein was observed. The trend of the sGCβ1 
protein expression largely corresponded to that of its mRNA. Temporal expression study 
(Figure 4.10) showed that incubation of CC with NaHS for up to 12 hours still resulted in 
significant increase in the sGCβ1 protein expression, suggesting that the up-regulation of 









Figure 4.11a sGCβ1 protein expression in rat corpus cavernosum (TMP) in control and 
NaHS treated group. Results are expressed in relative densitometric unit (d.u) as a 
percentage of medium control level, after normalizing to loading control pan actin. Data 
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Figure 4.11b sGCβ1 protein expression in rat corpus cavernosum (cytosolic fraction) in 
control and NaHS treated group. Results are expressed in relative densitometric unit (d.u) 
as a percentage of medium control level, after normalizing to loading control pan actin. Data 




4.8 RhoA/Rho-Kinase pathway 
 
 
4.8.1 Gene expression of RhoA, ROCK I and ROCK II 
  
The RhoA, ROCK I and ROCK II primers produced a single specific band/product during the 
real time PCR reaction. RhoA, ROCK I and ROCK II generated amplicons at approximately 
110 bp, 78 bp and 221 bp respectively. All of them corresponded to the expected PCR product 
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Dissociation curve analysis on the real time PCR product revealed a single peak when these 
primers were used, confirming that only one specific product was formed (not shown). NTC 
also showed no amplifications. As mentioned earlier, these observations suggest that the 
primers used here were specific enough for SYBR-based qPCR. 
 
As in the case with sGCβ1 (Figure 4.10), the medium was shown to affect the RhoA mRNA 
expression as incubation of CC with DMEM lowered the RhoA mRNA level significantly 
(result not shown). However, it was observed that when compared to medium control, NaHS 
did not affect the mRNA expression of RhoA in vitro in all the doses (0.1-10 mM) used 
(Figure 4.12). 
 
Very little/no ROCK I mRNA was detected by real time PCR. Some samples showed no 
amplification at all while some showed amplification after approximately 36 amplification 
cycles (result not shown), only when the amount of cDNA template was increased. The PCR 
amplification step had to be prolonged considerably (to > 50 cycles) before a PCR band could 
be visualised faintly on agarose gel. This result demonstrated that ROCK I mRNA was 
absent/present in low quantity in the corpus cavernosum, suggesting that its role in erectile 
response is likely to be limited. On the other hand, ROCK II mRNA could be detected 
relatively easily in CC. Generally, NaHS had no effect on the ROCK II mRNA expression 




Figure 4.12 Relative expression of RhoA mRNA in rat CC as assessed by real time PCR. 
Effects of different doses (indicated on the x-axis) of NaHS when incubated for 6 hours. 
Results, normalised to β-actin mRNA, are expressed relative to the medium control taken as 
1. Data shown are the mean ± SEM (n=3).  
 
  
Figure 4.13 Relative expression of ROCK II mRNA in rat CC as assessed by real time 
PCR. Effects of different doses (indicated on the x-axis) of NaHS when incubated for 6 
hours. Results, normalised to β-actin mRNA, are expressed relative to the medium control 





4.8.2 Protein expression of RhoA and ROCK II 
 
It was observed that NaHS significantly inhibited the expression of RhoA protein, both in the 
cytosol as well as plasma membrane (Figure 4.14a-b). Compared to control, lower RhoA 
protein level was present in the plasma membrane of CC treated with 0.5-1 mM of NaHS. At 
the relatively high dose of 10 mM, NaHS appeared to have opposite effect; it increased the 
RhoA protein expression in the plasma membrane. The response of the CC to NaHS did not 
appear to be graded; 0.5 and 1 mM of NaHS resulted in similar degree of inhibition of 
membrane-bound RhoA protein expression (approximately 40% reduction compared to 
control).  
 
It was also observed that NaHS lowered the expression of RhoA protein in the cytosol but this 
only occurred at the concentration of 0.5 mM. The results suggest that there exists a specific 
therapeutical window where H2S can inhibit the RhoA pathway and this window may be 
exploited for future development of H2S-based drugs to treat ED. Generally, NaHS seemed to 
affect RhoA only at translational but not transcriptional level since its effect on RhoA mRNA 



















Figure 4.14a RhoA protein expression in rat corpus cavernosum (TMP) in control and 
NaHS treated group. Results are expressed in relative densitometric unit (d.u) as a 
percentage of medium control level, after normalizing to loading control pan actin. Data 
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Figure 4.14b RhoA protein expression in rat corpus cavernosum (cytosolic fraction) in 
control and NaHS treated group. Results are expressed in relative densitometric unit (d.u) 
as a percentage of medium control level, after normalizing to loading control pan actin. Data 
shown are mean ± SEM (n=5-7). * P < 0.005 (decrease).  
 
 
Corpus cavernosum treated with NaHS had a lower protein expression of ROCK II. The 
membrane fraction of ROCK II was reduced to approximately half of its control level in 
NaHS-treated group (Figure 4.15a) whereas the cytosolic fraction was reduced to less than 
40% of its control value (Figure 4.15b). The inhibitory effect of NaHS on the protein 
expression of membrane ROCK II was apparent at a lower dose (0.1 mM) than on cytosolic 
ROCK II. While NaHS generally did not have any effect on ROCK II mRNA (Figure 4.13), it 
had significant effect on ROCK II protein expression (both on the membrane as well as in 
cytosol). Generally, the trend observed with ROCK II was consistent with that observed with 
RhoA; H2S only seemed to act at the level of protein but not mRNA for these two 













Figure 4.15a ROCK II protein expression in rat corpus cavernosum (TMP) in control 
and NaHS treated group. Results are expressed in relative densitometric unit (d.u) as a 
percentage of medium control level, after normalizing to loading control pan actin. Data 











Pan Actin  
NaHS 6hr 
mM MC 0.1 0.5 10 1 
NaHS 6hr 
mM MC 0.1 0.5 10 1 
ROCK II  
(cytosolic) 




Figure 4.15b ROCK II protein expression in rat corpus cavernosum (cytosolic fraction) 
in control and NaHS treated group. Results are expressed in relative densitometric unit 
(d.u) as a percentage of medium control level, after normalizing to loading control Pan actin. 




4.9 Effects of testosterone 
 
To investigate the involvement of testosterone on the effect(s)/ mechanism of action(s) of 
H2S, a comparative study was done between normal rats, castrated rats as well as 
normal/castrated rats with testosterone supplement. As expected, all the rats castrated were 
found to have low/negligible amount of plasma total testosterone of < 0.2 ng/ml compared to 
normal rats, which had an average total testosterone of 2.75 ± 0.5 ng/ml (Figure 4.16). Rats 
treated with NaHS had a similar amount of total testosterone (3.04 ± 0.2 ng/ml) in plasma, as 
control/untreated normal rats (2.75 ± 0.5 ng/ml) suggesting that NaHS did not affect 
testosterone production. Furthermore, all of the castrated rats receiving NaHS treatment had 
very low plasma testosterone level (< 0.34 ng/ml) which was similar to the testosterone level 
found in non-treated castrated rats (< 0.2 ng/ml). This also suggests that NaHS had no effect 






supplements increased the plasma testosterone level to >10 ng/ml (well beyond the normal 




Figure 4.16 Effects of castration and treatment on plasma total testosterone level. Each 
bar represents the proportion of samples with different concentration of testosterone in the 
respective treatment group (n=5).  
 
 
The magnitude of erectile response to electrical stimulations was generally much lower than 
normal in castrated rats, as indicated by the ICP/MAP ratio of 0.16 ± 0.01 compared to 0.36 ± 
0.02 in normal rats, which constituted a 55% reduction. NaHS pre-treatment increased the 
erectile response in both normal and castrated rats (Figure 4.17). This accentuation appeared 
to be higher in normal (43%) compared to castrated rats (30%). This was in contrast to 
testosterone supplements, which only improved erectile response in castrated but not normal 
rats despite these two groups having a similar testosterone level (> 10 ng/ml); castrated rats 
treated with testosterone had a higher ICP/MAP ratio of 0.28 ± 0.01 (P < 0.05) compared to 
untreated/castrated control with ICP/MAP ratio of only 0.16 ± 0.01 whereas normal rats 
treated with testosterone had a comparable ICP/MAP ratio (0.38 ± 0.02) to untreated/normal 




Figure 4.17 Effects of NaHS and testosterone treatment on the magnitude of erectile 
response (ICP/MAP) in normal and castrated rats. Each bar represents the mean ± SEM of 
measurements made in 5-7 animals. * P < 0.05 (increase/decrease) compared to normal 




Figure 4.18 Effects of NaHS and testosterone treatment on plasma NO concentration. 
Each bar represents the mean ± SEM of measurements made in 5-7 animals. * P < 0.05 
(increase) compared to normal control. # P < 0.05 (decrease) compared to castrated control. 
 
 
The effect of NaHS on plasma NO level was different in normal and castrated rats. Treatment 











6.0 µM in NaHS-treated group, P < 0.05) in normal rats but decreased plasma NO (from 30.0 
± 4.5 in castrated control to 11.0 ± 1.1 µM in castrated NaHS-treated group, P < 0.05) in 
castrated rats (Figure 4.18). 
 
 
4.10 Summary of results  
 
1. NaHS and sildenafil treatment in vivo increased the magnitude of erectile response 
(ICP/MAP) to electrical stimulation while L-NAME had the opposite effect. 
2. NaHS and sildenafil treatment in vivo increased the NO level in plasma and CC. 
3. NaHS treatment in vivo increased the H2S level in plasma and CC. 
4. NaHS increased the cGMP and cAMP level in CC in vitro. 
5. NaHS increased the eNOS mRNA expression in CC in vitro. 
6. NaHS increased the sGCα1 and sGCβ1 mRNA expression in CC in vitro. 
7. NaHS treatment in vitro increased the expression of membrane-bound sGCα1 but 
decreased that of cytosolic sGCα1 protein in CC. 
8. NaHS treatment in vitro increased the expression of both membrane-bound and cytosolic 
sGCβ1 protein in CC. 
9. NaHS treatment in vitro had no effect on RhoA and ROCK II mRNA expression in CC. 
10. NaHS treatment in vitro decreased the expression of both membrane-bound and cytosolic 
RhoA and ROCK II proteins in CC. 
11. NaHS treatment in vivo increased ICP response in both normal/untreated and castrated 
rats. 










5.1 Effects of H2S on erectile response  
 
Earlier studies showed that H2S exhibited pro-erectile effects in primates and rabbits (Srilatha 
et al., 2006; Srilatha et al., 2007). Here, it was shown that this pro-erectile effect was also 
present in the rat model. Treatment with H2S heightened the erectile response to electrical 
stimulation in rats (Figure 4.1), even after taking into account H2S’ effects on blood pressure. 
This is consistent with the finding by Villa Bianca and co-workers where direct, bolus 
injection of NaHS into the corpus cavernosum caused an increase in the intracavernosal 
pressure (d'Emmanuele di Villa Bianca et al., 2009). This study however, measured erectile 
response at the end of a long term (10 weeks) NaHS treatment. Therefore, the result is likely 
to be a measure of erectile function when the drug is at a ‘steady state’ concentration, 
following a chronic/regular dosing and after taking into account any elimination from the 
body by metabolic processes. This suggests that H2S can significantly improve erectile 
function and that when administered regularly in the long term, its metabolism still results in 
sufficient quantity of ‘active agents’ in the body to promote erectile function. To verify this, 
the H2S concentration and biosynthesis in the plasma and corpus cavernosum of these animals 
were measured. This will be discussed later in this section. 
 
Both NaHS and sildenafil magnified the ICP rise to electrical stimulation significantly; 
however, while sildenafil at the dose used in this study had little effect on blood pressure, 
NaHS caused considerable hypotension (Figure 4.1). This is not surprising considering that 
H2S is a vasorelaxant agent (Webb et al., 2008; Bhatia, 2005) and that the deletion of CSE 
can cause hypertension in mice (Yang et al., 2008). At therapeutic level, this can be a 
potential drawback similar to PDE-5 inhibitors, if H2S were to be used for treatment of ED, 
particularly in patients on nitrates. Identifying analog(s) of H2S that may have a split of 




It was demonstrated here that L-NAME significantly reduced the magnitude of erectile 
response, thereby confirming the active involvement of the NO/cGMP pathway in mediating 
erectile response. It was also shown that L-NAME caused hypertension which is consistent 
with data in the literature (Küng et al., 1995; Zicha et al., 2003) and expected since NO can 
regulate systemic vascular resistance and therefore affect blood pressure (Stamler et al., 
1994). Treatment with PAG caused a slight reduction in ICP but its ICP/MAP ratio was not 
significantly different from that of control i.e. it had little/no effect on erectile response at the 
dosage used in this study.  
 
5.2 Relationship between H2S, NO and erectile function 
 
This study showed that the increase in NO concentration after treatment with NaHS was 
correlated with a significant improvement in erectile function (Section 4.2, Figure 4.2). 
Considering that NO is the main gasotransmitter involved in erectile physiology (Burnett et 
al., 1992), it is likely that H2S improved erectile response by influencing the NO/cGMP 
pathway. NaHS-treated animals (shown to have an elevated level of H2S than control) 
exhibited considerably higher systemic and local (CC) level of NO compared to control 
animals, suggesting that H2S can facilitate the NO pathway, possibly by increasing the NO 
production and this increase may be partly responsible for the pro-erectile effect of H2S. This 
ability of H2S to elevate the NO level is suggestive of a cross talk between H2S and NO. 
Indeed, the presence of such a cross talk has been demonstrated in the vascular system earlier 
(Whiteman and Moore, 2009). The results from this study demonstrate the existence of this 
cross talk in the corpus cavernosum.  
 
It is evident that regular treatment with NaHS for 10 weeks resulted in an elevated level of 
H2S in the plasma as well as increased H2S-synthesizing capacity in the corpus cavernosum 
(Section 4.3). Since the measurement of H2S production in the CC was done by quantifying 
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the rate of release of H2S when the tissue (containing CSE/CBS) (Srilatha et al., 2008) was 
supplied with the enzyme’s substrate (L-cysteine) as well as co-factors, this experiment 
measured the tissue’s ‘H2S-synthesizing capacity’ and it was found that given sufficient and 
equal amount of substrate/co-factors, NaHS-treated animals possessed greater H2S-
synthesizing capability than non-treated (control) animals. This suggests a positive feedback 
mechanism, where H2S becomes a stimulator of its own production resulting ultimately in a 
significant elevation of the H2S level. It is likely therefore that the observed rise in plasma 
H2S was due partly to an accentuated CSE/CBS activity, stimulated by the exogenous H2S. 
Similarly, a recent study also demonstrates that onion extract (a rich source of sulphide) can 
increase endogenous H2S production in rat aorta (Li et al., 2011). Furthermore, studies on 
cardiovascular disease models have demonstrated that exogenous H2S increased CSE 
expression and activity, resulting in higher H2S level and production (Chunyu et al., 2003; 
Yan et al., 2004). The question of whether H2S treatment in this study increased endogenous 
H2S production through activity or expression of the CSE or CBS remains to be answered; 
further investigation is needed to verify this positive feedback mechanism. 
 
In the present study, the plasma H2S concentration ranged from 22-42 µM in all the treatment 
groups (Figure 4.3), which was well within the range reported by other groups (Section 
1.3.1.2). It has been shown that even in the presence of  > 30 µM of HS
-
, no disturbance in 
oxidative phosphorylation is observed since H2S gets rapidly oxidised in the mitochondria 
(Wang, 2002; Bartholomew et al., 1980; Nicholls and Kim, 1981)  i.e. at this concentration, 
H2S does not disturb cellular respiration to cause toxicity. Therefore, at the range of H2S 
concentration observed in this study (22-42 µM) H2S is unlikely to be toxic. It is possible that 
the positive feedback mechanism of H2S may be an evolutionary adaptation which serves as 
one of the ways in which H2S can counter its rapid oxidation by the mitochondria to 




Since the improvement in erectile function with NaHS treatment was correlated with both an 
increase in NO and H2S level/production (Section 4.1-4.3), it was difficult to pinpoint the 
relative contribution of each component to the improvement in erectile response (whether it 
was due to direct effect of H2S alone or due to the indirect effect of H2S on the NO/cGMP 
pathway or a combination of both). Further study to investigate this relative contribution may 
utilise a combination of NaHS and L-NAME treatment to determine if inhibition of NO 
production in the presence of H2S still results in a significant improvement in erectile 
response.  
 
Unlike NaHS, the improvement in erectile response that was observed in the sildenafil group 
was correlated only with increased NO level in plasma and corpus cavernosum; no elevation 
in H2S plasma level or H2S synthesizing capability was observed in this group. There have 
been reports of sildenafil increasing the expression of eNOS and iNOS mRNA and proteins 
(Das et al., 2005; Salloum et al., 2003; García-Cardoso et al., 2010)
  
in cardiac myocytes and 
mononuclear cells. Udenafil, an agent similar to sildenafil, has also been reported to increase 
the expression of eNOS and nNOS gene and protein in rat model of chemical diabetogenesis 
(Ahn et al., 2009). The increase in NO level that is observed in this study may be the result of 
such activation of NO-producing enzymes as shown by other groups. Taken together, it 
appears that the pro-erectile effect of sildenafil in a clinical setting is probably due to a 
combination of an elevated NOS activity and its PDE inhibitory activity downstream. What is 
interesting is the fact that while NaHS treatment (which increased H2S level and production) 
changed the NO level, sildenafil treatment (which increased NO level in plasma and CC) did 
not change the H2S level/production in this study; however in the vascular system, NO 
increased H2S production through stimulation of CSE (Zhao et al., 2001). Thus, the 
relationship between H2S and NO appears to be complex and there is currently no specific 




As seen from the results (Figure 4.1), L-NAME pre-treatment significantly reduced the 
magnitude of ICP response to electrical stimulation, an objective parameter of erectile 
function. This reduction was correlated with a decrease in the plasma NO (but not the NO 
level in CC) and an increase in plasma H2S (but not H2S-biosynthesizing capacity in CC) 
(Figure 4.2A & 4.3A). The reduction in plasma NO together with the rise in blood pressure 
that was observed in this group indicated that the L-NAME successfully inhibited NOS and 
blocked NO production. What these results suggest was that the reduction in NO level was 
probably partly responsible for the impairment in ICP response that was observed (Figure 
4.1). Secondly, high H2S level (~42 µM compared to 25 µM in control) in this L-NAME-
treated group did not seem to be sufficient to reverse/block this impairment. Overall, it 
appears that while H2S plays a role in erectile function, the NO/cGMP pathway probably is 
the major contributor for the cavernous-nerve mediated erectile response.  
 
How L-NAME caused an increase in plasma H2S level was not evaluated in this study but a 
similar phenomenon has been documented; L-NAME treatment upregulated CSE protein 
expression which was accompanied by a rise in H2S production (Chuah, 2009; Rong-na et al., 
2011). At this juncture, the possibility that other enzymes (CBS or MPST) besides CSE may 
contribute to this increase in H2S level, still cannot be excluded. In present study, L-NAME 
failed to lower the NO level in CC even though it successfully inhibited NO production at the 
systemic level. Since the drug was administered in vivo, this lack of local effect by L-NAME 
is likely to be a pharmacological effect of the drug i.e. failure of the delivery of the drug to the 
target organ (Lin and Lu, 1997). In this case, an in vitro study may be more useful in 
determining the effect of L-NAME at the tissue level.  
 
In summary, high level of NO (observed in sildenafil group) was associated with normal H2S 
level and production while low level of NO (observed in L-NAME group) was associated 
with high H2S level. High level of H2S (observed in NaHS group) on the other hand was 
associated with increased NO level. These observations are intriguing because they seem to 
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suggest that H2S may act as a backup system when the NO/cGMP pathway is compromised 
for example under pathological conditions such as endothelial dysfunction. One may 
hypothesise that the shortage of NO would trigger the production of H2S (possibly by 
upregulating CSE expression) and when H2S reached a certain level (quite possibly through 
positive feedback of its own formation), it would trigger the production of NO. This dual 
regulation system would have two advantages: firstly, H2S on its own has very similar 
properties to NO (i.e. both are vasorelaxants) and therefore by fulfilling the same function as 
NO, H2S can serve as a temporary system when there is shortage of NO until the NO level 
can be restored; secondly H2S functions to restore the NO level. In the context of erectile 
physiology, this second function is essential because high level of H2S in presence of low NO 
(observed in L-NAME group) appeared insufficient to restore erectile function back to 
normal. However, considering the importance of the NO/cGMP pathway, the redundancy 
provided by H2S may confer survival advantage from an evolutionary perspective. The idea of 
H2S acting as ‘back up’ for NO has also been broached by Li and others before; the authors 
proposed the existence of ‘endothelium-derived H2S’ which may have a similar function to 
endothelium-derived NO (Li et al., 2009a; Sanderson, 2009). 
 
Although an acute bolus administration of PAG (50 mg/kg) in rats had significantly lowered 
the ICP response in an earlier work from this lab (Srilatha et al., 2006), in this study, the 
chronic administration of PAG (50 mg/kg; twice weekly for 10 weeks) failed to lower the 
measured response to nerve stimulation (ICP) significantly. In fact, the PAG-treated rats also 
exhibited normal plasma and tissue H2S levels in this study. It follows that PAG failed to 
sufficiently inhibit H2S production and subsequently (either as a direct or indirect result) 
failed to impair erectile response. It may be important to note here that PAG is an inhibitor of 
CSE i.e. it would not inhibit other H2S-synthesizing enzymes such as CBS or MPST (Figure 
1.2). Thus, the failure of PAG to inhibit H2S production and erectile response may be due to 
the following: 1) since only one dose (50 mg/kg, ip, twice weekly for 10 weeks) was used it 
was not possible to exclude the possibility that PAG failed to inhibit CSE simply because its 
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effective concentration was not reached; Zhu et al used PAG at the same dose (50 mg/kg, ip) 
but with higher frequency (daily, for 7 days) (Zhu et al., 2007), this group’s dosing regimen 
had to be modified because a daily administration of PAG at this dose for 10 weeks (as 
opposed to the short period of 7 days) resulted in very high mortality rate; 2) any decrease in 
endogenous H2S production caused by the inhibition of CSE may be compensated by other 
H2S-producing enzymes as mentioned above. Considering that PAG failed to inhibit H2S 
production in general, its effect on NO level was also likely to be non-specific or even direct 
(i.e. not caused by low endogenous H2S). Although PAG inhibited CSE specifically by 
binding to the enzyme’s pyridoxal phosphate binding site, it may also exert effects on other 
enzymes. However, a search of the available scientific information to date failed to show any 
specific effect of PAG on NO synthesis.  
 
5.3 Effects of H2S on the cGMP and cAMP second messenger system 
 
Cyclic GMP is an important cellular mediator of NO signalling. This role is generally 
established from three main lines of evidence: 1) excellent correlation between the 
manipulation of cGMP level by endogenous NO and/or NO donor and the pharmacological 
effect (relaxation); 2) consistent findings that cGMP analogues and cGMP-specific PDE 
inhibitors mimic NO-dependent relaxations; and 3) the effects of sGC inhibitors in blocking 
NO-mediated relaxation (Ignarro, 2000). 
 
The binding of NO to sGC increases the activity of the enzyme which would subsequently 
increase the cGMP level (Ignarro, 2000). In the cell, cGMP may bind to three different kinds 
of intracellular receptor proteins namely: 1) cyclic nucleotide-dependent protein kinases e.g. 
protein kinase A (PKA) and PKG; 2) cyclic nucleotide PDE, primarily at allosteric sites on 
the enzymes; and 3) ion channels, especially those whose activities are amplified upon cGMP 
binding (Lincoln and Cornwell, 1993). Alternatively, cGMP may also get hydrolyzed by PDE 
enzymes (Juilfs et al., 1999). Generally, the effect of cGMP would depend on the expression 
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of specific receptor proteins. The corpus cavernosum expresses all three of these proteins and 
therefore the effect of cGMP in this context may have far reaching consequences as discussed 
below. 
 
To investigate whether the effect of H2S extends to the downstream mediator of the NO 
pathway, present study looked at its effect on cGMP at the cellular level in vitro. In CC, H2S 
was shown to cause a dose-dependent increase in cGMP level (Figure 4.4). In this respect, it 
confirms one of the earlier findings (Srilatha et al., 2008) where H2S was shown to elevate 
cGMP concentration in the rat CC. Bucci and co-workers also demonstrated that H2S elevated 
cGMP concentration in rat aortic smooth muscle cells and an over-expression of CSE in 
increased the intracellular cGMP level in a PAG-sensitive manner (Bucci et al., 2010).  
 
This effect of H2S on cGMP is significant because elevation of cGMP level has been known 
to be largely responsible for the relaxation of smooth muscle needed to produce erection 
(Kirby, 1999; Juilfs et al 1999). In fact, an increase in cGMP level is physiologically relevant 
in the context of erectile function because cGMP can activate PKG whose substrates, in turn 
are directly involved in the modulation of smooth muscle tone, in particular relaxation. Some 
of the physiologically important PKG substrates include: 1) MBS of MLCP which can 
modulate the activity of MLCP (PKG phosphorylates the MBS of MLCP to activate the 
enzyme) (Surks et al., 1999); 2) HSP-20, a 20kDa heat shock-related protein which can 
modulate smooth muscle contractility (Beall et al., 1997); and 3) phospholamban (PKG 
phosphorylates phospholamban to increase the Ca
2+
 uptake into the sarcoplasmic reticulum of 
smooth muscle cells, thereby lowering the Ca
2+
 level in cytosol and subsequently inducing 
relaxation) (Vrolix et al., 1988; Raeymaekers et al., 1988; Cornwell et al., 1991; Karczewski 
et al., 1992). PKG can also phosphorylate telokin to accelerate MLC dephosphorylation, 
giving rise to ‘Ca2+ desensitization’ (Wu et al., 1998). Another important PKG substrate 
would be KCa channel α subunit; activation of KCa channel by PKG would result in efflux of 
K
+
, giving rise to hyperpolarization and inhibition of voltage dependent Ca
2+
 channels in the 
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smooth muscle cell membrane, eventually resulting in relaxation (Alioua et al., 1998; Dora et 
al., 2002). In summary, cGMP through the action of PKG regulates the intracellular Ca
2+ 
level 
using several mechanisms of action. However, there is also evidence that cGMP can act as 
Ca
2+
 mobilizing messenger in a PKG-independent manner (Murthy and Makhlouf, 1998). 
Further studies are needed to investigate if the H2S-induced elevation of cGMP is 
accompanied by an increase in the activity or expression of PKG. Cyclic GMP can also 
activate PKA, however the level of cGMP in the cell normally fails to reach a high enough 
concentration (≥ 100 µM) (Wyatt et al., 2003) to cross-activate PKA (Ignarro, 2000). 
 
Interestingly, the H2S-induced elevation in cGMP concentration observed in this study 
occurred within a very short span of 30 minutes, suggesting that it could be partly responsible 
for the acute effect of H2S that was observed in other studies where intracavernosal injection 
of NaHS in vivo caused an almost instantaneous increase in ICP (d'Emmanuele di Villa 
Bianca et al., 2009). The very rapid response that H2S elicited here also suggests that 
modulation of cGMP level by H2S in this case was probably through changes in enzyme 
activity rather than expression. Since the assay in this study employed the use of PDE 
inhibitor IBMX, this increase was most probably caused by stimulation of the activity of sGC 
rather than by inhibition of PDE. There exists a distinct possibility that H2S may directly act 
on sGC to sensitise it towards NO by binding to an unknown allosteric site on sGC to 
modulate its responsiveness to heme ligand and regulate its catalytic rate. The benzylindazol 
derivative YC-1 is able to induce the sensitivity of sGC to NO through allosteric regulation, 
proving the existence of such sites on the enzyme which can regulate its activity (Ignarro, 
2000). The clinical implication of such direct stimulatory effect on sGC is interesting because 
it represents a promising new therapy for patients with ED who fail to respond to sildenafil or 
in cases where endogenous NO production is compromised to such an extent that inhibition of 
cGMP degradation alone has no beneficial effects. However, the possibility that H2S elevates 
cGMP by inhibiting PDE also cannot be ignored. Cell-free assay shows that NaHS can inhibit 
cGMP-PDE activity to a level that is comparable to inhibition by IBMX (Bucci et al., 2010). 
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The effect of NaHS in increasing cGMP level is also significantly heightened in COS-7 cells 
overexpressing PDE5 with the converse being true (overexpression of CSE increases the 
cGMP level in a PAG-sensitive manner while knockdown of CSE reduces the intracellular 
cGMP in rat aortic smooth muscle cells) (Bucci et al., 2010). Two possibilities as to how H2S 
may inhibit PDE activity exist: 1) PDEs are Zinc (Zn)-containing enzymes and removal of Zn 
abolishes their activity (Bender and Beavo, 2006); H2S has been known to bind to Zinc (Zn) 
(Szabó, 2007) and modulate the activity of Zn-dependent enzymes and 2) H2S may regulate 
the activity of PDE through post translational protein modification such as sulfhydration 
(Mustafa et al., 2009). 
 
To investigate the definitive cause of the net increase in cGMP, whether it was due to an 
increase in cGMP production or an accumulation due to inhibition of its breakdown, a 
comparative study of the effect of H2S on cGMP level in presence and absence of IBMX may 
be useful. Alternatively, the effect of H2S on cGMP in presence and absence of sGC inhibitor 
e.g. 1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one (ODQ) can also be investigated. 
 
It was not clear whether the effect of H2S in increasing the cGMP level was as a result of a 
direct effect of H2S on sGC/PDE and/or an indirect outcome of H2S’ effect in increasing the 
level of NO. The in vivo segment of this study focused on the effect of long term and ‘steady 
state’ concentration of H2S wherein H2S was found to increase the NO level at week 10 post-
treatment. However, the minimum length of time it may take for H2S to achieve this effect 
was not known. Nevertheless the possibility that H2S increased cGMP level by increasing the 
level of NO cannot be excluded. 
 
It seems that H2S also increased cAMP level, although this only occurred with a particular 
dose (1 mM). An increase in cAMP can effectively contribute to erectile response; as a matter 
of fact PGE1 has been used as a relatively effective treatment for ED (Virag and Adaikan, 
1987; Heaton et al., 2001). However, while higher level of cAMP than cGMP was observed 
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in CC, the effect of H2S treatment on cAMP level seemed to be much less pronounced than on 
cGMP and in this case it was unknown if this H2S-induced increase in cAMP was sufficient to 
contribute significantly to erectile response. 
 
The concentration of cyclic nucleotides needed to activate PKG generally depends on the 
phosphorylation state and isoform of the enzyme; PKG can be activated either by high 
concentration of cAMP or low concentration of cGMP (Ignarro, 2000). This implies that by 
increasing the cGMP level by 3 folds, H2S is likely to have important physiological 
implications. What is interesting to note is that NO seems to be involved in the regulation of 
PKG; chronic exposure to NO-donors at high concentration has been shown to suppress PKG 
mRNA in vascular smooth muscles (Soff et al., 1997). Given that H2S can induce NO 
production, it is not too far-fetched to suggest that H2S may act as both stimulator and 
regulator of the cGMP/PKG signal. The ability of H2S to induce cGMP production serves as 
further evidence of the existence of cross talk between H2S and NO/cGMP pathway in CC. 
 
5.4 Effect of H2S on eNOS 
 
Studies investigating the cross talk between H2S and NO pointed out the involvement of 
eNOS (Chuah, 2009). In the present study, it was found that H2S increased the expression of 
eNOS mRNA by as much as 4 folds in the span of 6 hours (Figure 4.6). There was also some 
indication that this increase may be time-dependent. Endothelial NOS may contribute partly 
to the H2S-induced increase in NO level. Considering that eNOS upregulation is time 
dependent, it was possible that chronic/long term treatment with H2S led to sustained increase 
in eNOS expression which could subsequently contribute to the NO pool. Coincidentally, in 
vivo treatment with H2S also elevated the NO level in plasma and CC (Figure 4.2). 
 
Study by Kubo and others shows that H2S can inhibit recombinant eNOS (Kubo et al., 
2007a), which may appear contradictory to the finding in this study (which demonstrated that 
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H2S increased NO production). Their study however, was done in a cell free system in vitro 
(as opposed to in vivo) and therefore did not really reflect normal physiological condition 
where endogenous factors may interfere with this inhibition e.g. in presence of excess NOS 
co-factor BH4, NaHS failed to inhibit eNOS (Kubo et al., 2007b). Secondly, the effective 
concentration range of NaHS which was shown to inhibit eNOS in this enzyme assay was 
consistent with dose that caused contractile activity in the tissue bioassay (Kubo et al., 
2007a). Thirdly, eNOS inhibition alone would not necessarily result in a reduction of the total 
pool of NO since both nNOS and iNOS can also contribute to this pool (Bruckdorfer, 2005). 
In fact, the finding by Kubo et al is controversial considering that there have been conflicting 
reports; for example NaHS was found to increase the expression of phosphorylated (at 
position Serine 1177) eNOS which was consistent with eNOS activation, in ischemia-
reperfusion study (Yusof et al., 2009). An independent group has also verified this result; H2S 
was found to stimulate production of NO by activating eNOS by phosphorylating it at Serine 
1177 (Predmore, 2009). It seems that H2S may have some effects on NOS activity and 
investigating the effect of H2S on the expression of NOS alone may be incomplete. 
 
5.5 Effects of H2S on sGC 
 
Two types of GC have been identified:  cytosolic sGC and membrane-bound particulate GC 
(pGC; it belongs to a group of receptor-linked enzymes with one membrane spanning 
domain) (Ignarro, 2000). However, unlike the NO-sensitive sGCs, pGCs are not stimulated by 
NO (Fessenden and Schacht, 1997) therefore this study focused on sGC but not pGC. 
 
Soluble GC has been purified by several groups and is found to be comprised of an α (large) 
and β (small) subunit (Gerzer et al., 1981; Humbert et al., 1990; Stone and Marletta, 1995). 
Currently, two isoforms of each subunit have been identified, namely α1, α2, and β1, β2 
respectively. The α1/β1 isoforms constitute the predominant/most abundant dimers present 
and active in mammals; they have been sequenced and cloned from rat, mouse, bovine and 
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human (Koesling et al., 1990; Nakane et al., 1990; Zabel et al., 1998). In mammalian tissue, 
α1/β1 isoforms are also distributed ubiquitously in the heart, kidney, lung, muscle, spleen and 
brain (Sharina et al., 2000; Budworth et al., 1999). Dimers comprising of α2 and β1 have also 
been identified but they appear to exist preferentially in specialised tissues e.g. placenta 
(Russwurm et al., 1998) and central nervous system (Russwurm et al., 2001) and comparison 
of the heterodimers α1/β1 and α2/β1 does not reveal any differences between the two in terms 
of NO sensitivity, kinetic properties, heme content, and responsiveness towards modulators 
(Ignarro, 2000). For all these reasons, the scope of this study was narrowed to sGCα1 and β1. 
 
It was found that H2S moderately increased the sGCα1 mRNA expression in a dose dependent 
manner in CC; however, such an upregulation was not observed at the protein level (Section 
4.7). Instead, H2S appeared to be involved in the translocation of sGCα1 protein from the 
cytosol to the plasma membrane. The NO-sensitive sGC was initially thought to be entirely 
cytosolic and hence it was termed ‘soluble’ GC. Recent studies have challenged this 
designation of sGC as a purely cytosolic enzyme. Approximately 20% of the sGC in the rat 
heart for example is found in the membrane fraction (Zabel et al., 2002). Other tissues such as 
skeletal muscle, colon, brain cortex, cerebellum and adrenal gland have also been found to 
contain membrane-associated sGC (Zabel et al., 2002). Indeed, this study also demonstrated 
that such membrane-bound sGC existed in the CC. At moderate to high doses, H2S increased 
the expression of membrane-bound sGC α1 protein but decreased the expression of cytosolic 
sGCα1, suggesting that rather than modulating the overall protein expression of sGCα1, H2S 
was involved in the cellular translocation of sGCα1 from cytosol to the plasma membrane. 
This finding has a significant implication because studies have found that translocation of 
sGC to the plasma membrane modulates the enzyme’s activation properties and sensitises it to 
NO (the dose-response curve to NO donor is shifted to the left in membrane-associated sGC 
compared to cytosolic sGC) (Pyriochou and Papapetropoulos, 2005); this higher sensitivity is 
thought to be related to the higher stability of the membrane-bound sGC and NO complex and 





(Zabel et al., 2002). In the context of endothelial cells, it is hypothesised that the translocation 
of sGC to the plasma membrane would bring the enzyme closer to the ‘sphere of influence’ of 
NO, given that NO has high solubility in lipid, a very short T1/2 in aqueous environment and 
that NO is generated predominantly in plasma membrane in endothelial cells. This H2S-
induced translocation of sGC to the plasma membrane is an intriguing finding given that H2S 
was also able to induce NO production (Section 4.2). It appeared that H2S was greatly capable 
of enhancing NO signalling through a multipronged approach viz, by boosting the NO level 
and by sensitizing the sGC to NO at the same time.  
 
Time point study was not done in this case due to several major challenges. It was discovered 
that the medium used to dissolve NaHS (DMEM) had some effects on sGCα1 protein 
expression (this was done by comparing the protein expression in untreated CC with that in 
CC treated with the medium; result not shown). This effect was also observed with other 
proteins e.g. sGCβ1 (please refer to Figure 4.10). This means that for each time point used, a 
separate vehicle/medium control was needed i.e. more tissues were required. Considering the 
limited number of animals and amount of corpus cavernosum tissue available in this study, 
this was not practical. Moreover, antibiotics were not added to the medium as they can affect 
protein expression by binding to ribosomes (Pommerville, 2010). Absence of antibiotics 
increased the risk of bacterial contamination, making studies with long incubation period not 
ideal.  
 
It was found that H2S also increased the expression of sGCβ1 mRNA in CC (it is still unclear 
if this increase was due to an increase in transcription or an increase in the stability of the 
mRNA). More importantly, this upregulation was reflected at the protein level; H2S dose-
dependently increased the expression of sGCβ1 in both cytosol and plasma membrane. This 
protein upregulation also appeared to be sustained for at least up to 12 hours. The residues 
needed for substrate recognition and catalysis are distributed on the two chains of the 
heterodimeric α1/β1 sGC enzyme; therefore, even though each subunit possesses a catalytic 
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domain, the presence of both is essential for enzymatic activity. Nevertheless, most of sGC’s 
regulatory features are determined by the β1 subunit. Experiments using truncated subunits 
reveal that the N-termini of both α1 and β1 subunits are required for proper heme binding 
(Foerster et al., 1996; Ignarro, 2000). However, these 2 subunits appear to contribute 
unequally, with β1 being the primary heme binding subunit (Zhao and Marletta, 1997); 
mutation on cysteines 78 and 214 of the β1 subunit yields sGC with lower heme-binding 
affinity, whereas mutation on equivalent residues on the α1 subunit does not alter the 
enzyme’s sensitivity to NO (Friebe et al., 1997). This prosthetic heme group serves as the 
acceptor site for NO on the sGC (Humbert et al., 1990; Stone and Marletta, 1995) and its 
presence is required for the stimulatory effect of NO (Craven and DeRubertis, 1978; Ignarro 
et al., 1982; Ohlstein et al., 1982). Histidine-105 residue of the β1 subunit has been identified 
as the axial ligand of the heme group (Zhao et al., 1998; Wedel et al., 1995). There is 
evidence that it is the displacement of this axial ligand by NO that triggers the conformational 
change which results in the increase in enzyme turnover/activity (Martin et al., 2003; Dierks 
et al., 1997; Ignarro, 2000). Therefore, the increase in sGCβ1 expression that was induced by 
H2S potentially represents an increase in sGC’s ‘heme binding capacity’ for NO i.e. H2S is 
likely to contribute to the regulation of sGC by altering the enzyme’s sensitivity towards NO. 
 
What is interesting to note here is that H2S had distinct effects on the different subunits of 
sGC; it induced translocation of the α1 subunit but increased the expression of the β1 subunit. 
Considering that the enzymatic activity of sGC requires the presence of both subunits, it is 
still unclear whether this increase in the expression of the β1 subunit alone is sufficient to 
contribute to higher production of cGMP by the sGC. Further studies on the localization of 
both subunits would prove to be useful in determining whether the α1 subunit co-localise with 
β1, in particular whether the translocation of α1 to the plasma membrane is accompanied by 
the β1 subunit and also in determining where the ‘extra’ β1 subunits (obtained as a result of 




Regardless of whether or not H2S increased the net activity of sGC eventually, it is quite clear 
that H2S is involved in the regulation of sGC, in particular in modulating the enzyme’s 
sensitivity towards its ligand NO. Moreover, it was found that NO-activation of sGC was 
potentiated under reducing conditions e.g. in presence of ascorbate, dithiothreitol, glutathione 
or cysteine (Ignarro, 2000). With pKa of 7.04, H2S at the physiological pH of 7.4 can 
essentially provide a reducing environment in the body which potentially can contribute to the 
potentiation of sGC’s activation by NO. This means that physiologically, as H2S increased 
NO production (Figure 4.2), it may also enhance the ability of the NO generated to potentiate 
the activation of sGC at the same time. 
 
5.6 Effects of H2S on RhoA/Rho-Kinase pathway 
 
As mentioned in section 1.3.2.5, RhoA is a small monomeric GTPase; it is inactive in its 
GDP-bound state and activated when it is bound to GTP. These two forms of RhoA exhibit 
different localization profiles. Agonist induced activation of G-protein-coupled receptor 
(GPCR) brings forth an exchange of GDP for GTP on RhoA (Webb, 2003). The enzyme 
guanine nucleotide exchange factors (RhoGEFs) cause dissociation of RhoA from its binding 
partner, Rho-guanine dissociation inhibitor (RhoGDI). This causes the inactive RhoA in the 
cytosol to translocate to the membrane (Bokoch et al., 1994; Gong et al., 1997b; Gong et al., 
1997a). One of the downstream targets of RhoA is the serine/threonine protein kinase, Rho-
Kinase (ROCK) (Leung et al., 1995; Amano et al., 1996). Two isoforms of ROCK have been 
identified in the mammalian system: ROCK I (also known as ROKβ or p160ROCK) (Ishizaki 
et al., 1996) and ROCK II (also known as ROKα) (Leung et al., 1996). The RhoA/Rho-
Kinase pathway has been implicated in erectile physiology, in particular in the maintenance of 
the flaccid or contracted state of the penis through ‘Ca2+-sensitization mechanism’ involving 




As previously discussed in section 1.3.2.4, smooth muscle relaxation can be brought about 
either by a decrease in intracellular Ca
2+
 concentration or through ‘Ca2+-desensitization’ of the 
contractile apparatus. This means that a thorough investigation on the mechanism of action of 
H2S in CC should include both its effect (facilitatory) on relaxation of the corporal smooth 
muscle as well as its effect (inhibitory) on the contractile pathway (since both may give rise to 
pro-erectile effects). 
 
The present study found that generally, H2S had no effect on the mRNA expression of both 
RhoA and ROCK II, while ROCK I was hardly detected in CC (Section 4.8.1). However, H2S 
reduced the expression of RhoA protein in both cytosol and plasma membrane (Section 
4.8.2). This means that not only did H2S downregulate the general expression of RhoA 
protein but it also effectively reduced the expression of active RhoA. Moreover, this H2S-
induced decrease in RhoA was correlated with a downregulation of both cytosolic and 
membrane-bound ROCK II protein, suggesting that H2S’ effect on RhoA successfully resulted 
in modulation of the downstream mediators in this pathway and was likely to have some 
functional implication. ROCK II proteins are normally localised in the cytosol under resting 
state and are translocated to the membrane upon activation by Rho (Leung et al., 1995); this 
means that H2S not only downregulated the general expression of ROCK II but it also reduced 
the expression of the active ROCK II (an effect that is similar to that observed with RhoA). 
This finding is important because MLCP is an important downstream target protein of ROCK 
II. The MLCP holoenzyme is comprised of 3 subunits: a small 20 kDa non catalytic subunit 
(M20), a catalytic subunit of type 1 phosphatase (PP1) and a 100 kDa MBS (which is also 
known as myosin phosphatase target subunit or MYPT) (Hartshorne et al., 1998). ROCK II 
has been found to phosphorylate MBS of MLCP at threonine 695/697 (chicken/rat) and 
threonine 850/855 (Kawano et al., 1999). Phosphorylation of Thr 695 seems to be required 
and sufficient for inhibition of the catalytic activity of PP1 (Feng et al., 1999), while 
phosphorylation of Thr 850 dissociates PP1 from myosin which also renders the MLCP 
inactive (Velasco et al., 2002). This means that H2S-induced reduction in ROCK II 
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expression/activity was likely to increase the activity of MLCP, giving rise to smooth muscle 
relaxation. 
 
The ROCK II can also directly phosphorylate serine 19 residue of the MLC, which is the 
same residue that gets phosphorylated by MLCK (Amano et al., 1996); phosphorylation of 
this residue is essential in facilitating the activation of myosin ATPase by actin (Kamisoyama 
et al., 1994; Bresnick et al., 1995). Therefore, it appears that ROCK II can increase cellular 
contractility via dual effects on MLC and MLCP and this will effectively modify the 
sensitivity of smooth muscle contraction to changes in Ca
2+
 concentration. Considering the 
role that ROCK II plays in smooth muscle contraction, it is likely that the downregulation of 
ROCK II by H2S will contribute substantially to smooth muscle relaxation. 
 
In general, H2S seemed to affect the RhoA/Rho-Kinase pathway at translational but not 
transcriptional level. In this study, it was also shown that when administered in vivo, H2S 
improved erectile response i.e. the pro-erectile effect of H2S appeared to be associated with 
downregulation of RhoA and ROCK II proteins in the CC. This possibility is supported by the 
finding that membrane-bound (active) RhoA is higher in aged compared to young rats and is 
correlated with lower ICP/MAP (Jin et al., 2006). Moreover, inhibition of RhoA activity by 
over-expressing dominant negative RhoA in CC improves erectile function (Jin et al., 2006; 
Chitaley et al., 2002).  
 
The reduction in RhoA and ROCK II protein expression observed in this study can be 
correlated to an increase in eNOS mRNA expression as well as cGMP level in CC. Studies 
have shown that not only is RhoA/Rho-Kinase pathway involved in erectile biology, but it is 
also likely to be interlinked with the NO pathway (Pintérová et al., 2011). Rho-Kinase and 
eNOS are found to co-localise in the endothelium of CC. The penile tissue of streptozotocin 
(STZ)-induced diabetic rats has higher RhoA and ROCK II protein level but lower eNOS 
protein and cGMP compared to control. Transfection of these STZ diabetic rats with 
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adenovirus encoding dominant negative RhoA (which lowers the penile RhoA and ROCK II 
protein level) restores the eNOS protein and cGMP level to that observed in control 
(Bivalacqua et al., 2004). The ROCK II mRNA and protein are also found to be upregulated 
in the CC of eNOS knockout mice (Priviero et al., 2010). Moreover, there is also evidence 
that the RhoA/Rho-Kinase pathway is implicated in the vasorelaxation induced by NO and 
vice versa.  Both L-NAME and ODQ shift the dose response curve of Rho-Kinase inhibitor 
Y-27632 to the right while Y-27632 enhances SNP-induced relaxation in coeliac artery 
smooth muscle (Teixeira et al., 2005). On the other hand, cGMP/cGK pathway can inhibit 
RhoA and block RhoA-induced Ca
2+
 sensitization in vascular smooth muscle since cGK can 
phosphorylate RhoA at serine 188 residue and cause the translocation of membrane-bound 
RhoA to the cytosol, rendering it inactive (Sauzeau et al., 2000). There is also evidence that 
cGMP can bring about phosphorylation of serine 695 (human isoform) of the MLCP, which 
effectively increases the cayalytic activity of MLCP by blocking phosphorylation at threonine 
696 (the human isoform of rat’s Thr 697) (Wooldridge et al., 2004). This means that in this 
study, H2S - by elevating the cGMP level - may indirectly cause the translocation RhoA to the 
cytosol (and therefore its inactivation) through the action of cGK or directly activate MLCP 
by blocking the inhibition caused by phosphorylation at Thr 697 residue. 
 
The results presented here were consistent with evidence in the literature i.e. lower RhoA 
expression was associated with higher eNOS and cGMP level in CC. However, the cause and 
effect relationship between RhoA and NO/cGMP is still unresolved. With the observed 
effects on both pathways, it is unknown if H2S first affected (downregulated) RhoA and/or 
Rho-Kinase which then caused the upregulation of eNOS and cGMP level or if the 
downregulation of RhoA was a result of H2S-induced upregulation of eNOS and cGMP level.  
 
Moreover, it also appears that RhoA/Rho-Kinase signalling has an NO-independent 
component since inhibition of this pathway (while sufficient to cause relaxation of the 
corporal muscle) is not completely blocked by inhibitors of NOS (L-NAME) and sGC 
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(methylene blue) (Chitaley et al., 2001). This is not surprising considering that ROCK II can 
affect MLC and MLCP directly (as has been discussed above), without any apparent 
requirement for the presence of either NOS or sGC.  
 
In general, the improvement in erectile function brought about by H2S may be related to: 1) 
its ability to interfere directly with the RhoA/Rho-Kinase pathway - by downregulating RhoA 
and ROCK II - which gave rise to inhibition of the contractile activity of the corporal smooth 
muscle, 2) its ability to strengthen NO signalling (by upregulating eNOS, increasing NO 
production and cGMP level) which gave rise to corporal smooth muscle relaxation or 3) a 
combination of both, which involves a ‘cross-talk’ between RhoA/Rho-Kinase and NO 
pathway. 
 
5.7 Effects of testosterone 
 
To study the nature of the cross talk between H2S and NO, the role of testosterone in the 
relationship between the two pathways was investigated. Castration did not completely 
abolish the rise in ICP to electrical stimulation but it caused a significant decline in the 
magnitude of erectile response (Section 4.9). This is consistent with previous report which 
shows that erectile response is comprised of both androgen-dependent and independent 
components (Mills et al., 1994). In this study, it was observed that in normal rats, NaHS 
improved erectile response and this was correlated with an increase in plasma NO, in 
presence of normal level of total testosterone. In castrated rats, NaHS also improved erectile 
response in presence of low/negligible amount of total testosterone, but this was not 
correlated with a high plasma NO. 
 
In other words, H2S increased the magnitude of erectile response in both normal and castrated 
rats, suggesting that testosterone is not a requirement for the pro-erectile effects of H2S. 
However, H2S appears to be more effective in improving erectile response in normal 
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compared to castrated animals. This may be attributed to several factors: 1) testosterone may 
act specifically to enhance the responsiveness of vascular smooth muscle to 
neurotransmitters/gasotransmitters as was shown in the study by Mills and co-workers (Mills 
et al., 1992), 2) testosterone may improve the relaxation of the vascular smooth muscle which 
regulates blood flow into the cavernous sinuses during erection (Mills et al., 1996), 3) 
testosterone may directly increase endogenous H2S production by increasing the enzymatic 
conversion of L-cysteine to H2S (Bucci et al., 2009), which together with the exogenous H2S 
supplied would elevate the final H2S concentration in the body.  
 
Interestingly, testosterone supplements improved erectile response only in castrated rats but 
not normal rats. It appears that testosterone is important for erectile function but that a 
maximum threshold of testosterone level or ‘saturation point’ exists where any addition 
beyond this point does not improve the erectile function anymore i.e. only testosterone in 
physiological range exerts beneficial effect. In the present study, H2S did not seem to affect 
testosterone production, suggesting that while testosterone may confer some pro-erectile 
effects on its own (as discussed above), the pro-erectile effects of H2S was not as a result of 
testosterone effects. In summary, H2S did not require testosterone for its pro-erectile effects 
but these effects may be augmented in presence of testosterone. 
 
After castration and/or testosterone treatment, changes in plasma NO were not statistically 
significant, suggesting that testosterone level is unlikely to be a modulator of the plasma NO 
level (Figure 4.18). Castration lowered plasma testosterone, which was associated with a 
significant reduction in erectile response (but not plasma NO) and this impairment in erectile 
response could be restored partially by treatment with NaHS and/or testosterone supplement. 
It was interesting to note that while H2S improved erectile response in both normal and 
castrated animals, it increased plasma NO only in normal animals. In fact, it was observed 
that H2S reduced plasma NO in castrated rats. This suggests that the role of H2S in erectile 
function may differ in physiological and pathological conditions and that while H2S may 
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improve erectile response in normal animals by increasing NO production, it seems to 
improve erectile function in castrated animals through other means. Testosterone is clearly 
implicated in the cross talk between H2S and NO but the mechanism of action of H2S appears 
to be different depending on the testosterone level. In low testosterone environment (such as 




























The results of this study lead to the proposition that the pro-erectile effect of H2S is achieved 
through multiple mechanisms of action (Figure 6.1). Firstly, H2S seemed to be involved in a 
cross talk with the NO/cGMP pathway; it was capable of increasing NO production, eNOS 
mRNA expression as well as cGMP level in the cavernosum. Testosterone is likely to be 
implicated in this cross talk. More specifically, high testosterone level seemed to favour the 
cross talk while low testosterone seemed to cause H2S to ‘switch’ to an NO-independent 
mechanism for its pro-erectile effect. Moreover, the local hormonal milieu could also 
influence the ‘magnitude’ of the H2S-induced improvement in erectile function. With respect 
to NO pathway in erectile physiology, H2S seemed to play a ‘supportive’ role, amplifying NO 
signalling through dual action of increasing NO production and sensitizing the sGC towards 
NO. Interestingly, it appeared that H2S could auto-regulate its own production through a 
positive feedback and potentially, acted as a backup when the NO pathway was compromised.  
 
 




Secondly, H2S was involved in the downregulation of important components in the contractile 
pathway viz, RhoA and ROCK II proteins. Looking at the myriad of possible mechanisms of 
action of H2S, one may propose that the effect of H2S (and its mechanism of action) may 
differ depending on the local environment e.g. the relative expression of K
+
ATP channels, PDE 
isoforms expressed, amount of cAMP/PKA, cGMP/PKG and H2S in a particular tissue. 
Future work can look at the relative contributions and importance of the different mechanism 
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